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Chapter 4
Toward an effective exome-based genetic testing 




Purpose We evaluated the diagnostic yield in paediatric dilated cardiomyopathy (DCM) of 
combining exome sequencing (ES)-based targeted analysis and genome-wide copy-number 
variation (CNV) analysis. Based on our findings, we retrospectively designed an effective 
approach for genetic testing in paediatric DCM.
Methods We identified 95 patients (in 85 families) with paediatric onset of DCM. We initially 
excluded 13 of these families because they already had a genetic diagnosis, leaving a total of 
31 probands for single-nucleotide polymorphism (SNP) array and trio-ES. We used Human 
Phenotype Ontology (HPO)-based filtering for our data analysis.
Results We reached a genetic diagnosis in 15/31 (48.4%) families. ES yielded a diagnosis in 
13 probands (13/15; 86.7%), with most variants being found in genes encoding structural 
cardiomyocyte components. Two large deletions were identified using SNP array. If we had 
included the 13 excluded families, our estimated yield would have been 54%.
Conclusion We propose a standardized, stepwise analysis of (i) well-known cardiomyopathy 
genes, (ii) CNVs, (iii) all genes assigned to HPO cardiomyopathy, and (iv) if appropriate, genes 
assigned to other HPO terms. This diagnostic approach yields the highest increase at each 
subsequent step and reduces analytic effort, cost, the number of variants of unknown clinical 
significance, and the chance of incidental findings.




Dilated cardiomyopathy (DCM), characterized by dilation and impaired contraction of the left 
ventricle or both ventricles, is the most common type of cardiomyopathy (CM) among children 
younger than 18 years, with an incidence of 0.57 (95% CI: 0.52-0.63) per 100,000 children in 
the United States.1 The aetiology of paediatric DCM encompasses most of the genetic causes 
that also lead to isolated CM in adults2,3, and is usually autosomal dominantly (AD) inherited. 
However, in 14% of paediatric cases, DCM is associated with extracardiac features, pointing 
toward a wider spectrum of causes, including malformation syndromes, neuromuscular diseases, 
and metabolic disorders.1 These are often de novo cases or show an X-linked, autosomal recessive 
(AR) or mitochondrial inheritance pattern. Furthermore, copy-number variants (CNVs) may be 
identified in patients with multiple congenital anomalies and/or intellectual disability presenting 
with DCM4,5 as well as in patients with isolated DCM.6-9
The cause of DCM in children is an independent predictor of the combined outcome of death 
or transplantation.1 An early genetic diagnosis is therefore very important in determining the 
aetiology, disease course, and prognosis, and may guide rational and personalized treatment 
choices. In addition, the diagnosis has major implications for family screening and provides 
insight into the risk of recurrence.
The high degree of genetic heterogeneity in paediatric DCM can currently be addressed via 
next-generation sequencing (NGS). Most diagnostic labs have developed a targeted NGS 
panel for adult-onset DCM, but this does not generally encompass the most common and up-
to-date neuromuscular, syndromic and metabolic causes of DCM in childhood. Moreover, the 
continuous discovery of new disease genes makes it difficult for diagnostic labs to keep up to 
date on all the genes identified as being involved in paediatric CM; this is a major disadvantage of 
targeted sequencing using an enriched gene panel. By contrast, exome sequencing (ES), followed 
by targeted analysis of a regularly updated gene panel, has increasingly become the first-choice 
approach for heterogeneous diseases (see refs. 10-13 for examples). Pugh et al. showed that the 
detection rate of pathogenic variants increased from 7-10% to 27-37% by including larger 
numbers of genes, but there is an increased likelihood of identifying variants of uncertain clinical 
significance (VUS)2 and of incidental findings (IFs) that do not explain the patient’s phenotype. 
Human Phenotype Ontology (HPO) has become a useful tool in precision medicine by providing 
standardized terms to describe phenotypic abnormalities. Each term in the HPO is linked to 
associated diseases listed in Online Mendelian Inheritance in Man (OMIM) and to related genes 
by a combination of automated matching of the OMIM Clinical Synopsis to HPO term labels and 
manual curation of each term.14-17 These HPO terms are updated monthly and can be used for 
‘personalized’ targeted data analysis, thereby reducing the chance of VUS and IFs.
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There have been few reports on the diagnostic yield of genetic testing in paediatric DCM. Only 
one study reported a genetic cause of DCM, in 15 of 41 children (37%); familial disease in this 
cohort was high (35/41 cases, 85%) and only a limited set of 15 genes was sequenced in 13 
patients.18 In Pugh and colleagues’ cohort,2 37% were paediatric DCM cases but an overall 
diagnostic yield for their paediatric population was not reported. Both studies and current 
recommendations19,20 endorse genetic testing in the paediatric population. Schedules that 
define the order of analyses can help reduce the analytical effort needed to detect a genetic 
cause while minimizing the chance of IFs and the number of VUS. As far as we know, there are 
no studies reporting the yield and most effective diagnostic approach for genetic testing in 
patients with childhood-onset DCM.
We therefore had two aims. The first was to evaluate the diagnostic yield of trio-ES-based 
targeted analysis of genes involved in paediatric DCM in a cohort of thoroughly phenotyped 
patients, irrespective of their possible disease aetiology. Since our current variant-calling 
pipeline does not detect CNVs (apart from small insertion-deletions), all probands were also 
subjected to CNV analysis. The second aim was to determine, on the basis of these findings, 
the optimal diagnostic approach for establishing a genetic diagnosis in as many patients as 
possible. This involved obtaining the highest increase in yield for each subsequent diagnostic 
step while minimizing the chance of IFs and the number of VUS, in line with international 
recommendations.20





The University Medical Centre Groningen’s (UMCG’s) medical research ethics committee 
approved this study (approval no. 2014092), and written informed consent was obtained from 
all participants or their legal representatives.
We identified 95 patients (from 85 families) with familial and nonfamilial DCM or a mixed cardiac 
phenotype with age of onset of CM <18 years. These included patients with extracardiac features 
or possible myocarditis, or childhood cancer survivors who developed DCM after anthracycline 
treatment, as well as patients who experienced partial recovery from their DCM (Supplemental 
Tables 1–3). All patients were referred to either UMCG or Leiden University Medical Centre 
(LUMC), The Netherlands, between May 1993 and April 2017 for genetic counselling. DCM 
was defined by the presence of left ventricle (LV) dilatation (LV end-diastolic dimension >2 SD 
above mean for body surface area) and systolic dysfunction (fractional shortening or LV ejection 
fraction >2 SD below mean for age) not explained by abnormal loading conditions20 or evidence 
for DCM from autopsy.
Patients with a genetic diagnosis explaining their phenotype and the course of their disease 
were excluded from our ES and CNV analysis for this project (Supplemental Table 1). We did, 
however, offer ES to patients with a (likely) pathogenic variant that may not fully explain their 
phenotype or disease course, for example, a 9-year-old patient with a dramatic disease course 
who carried a truncating TTN variant, which is usually associated with adult onset and a relative 
benign course.21 We recontacted all the remaining gene/mutation-elusive DCM patients who 
had been evaluated before the introduction of diagnostic ES.
All patients were phenotyped by a cardiologist and clinical geneticist, sometimes accompanied 
by a paediatric neurologist, all of whom reviewed the case. The clinical geneticist examined the 
patient to look for dysmorphisms and other extracardiac features at the time of counselling for 
ES and CNV analysis and took a three-generation family history. 
CNV analysis and homozygosity mapping (single-nucleotide polymorphism (SNP) array)
Genomic DNA from the affected child and its parents was extracted from peripheral blood or 
fibroblasts. Genome-wide genotyping, using HumanCytoSNP-850K SNP array according to 
the manufacturer’s protocols (Illumina, San Diego, CA), was performed to identify CNVs and/




Exome sequencing and data analysis
Exome sequencing and variant calling are described in the Supplementary Materials and 
methods. Briefly, the exome was captured with the Agilent Sureselect XT Human All Exon 
V5 or V6 kit (Agilent, Santa Clara, CA). Exome libraries were sequenced on an HiSeq2500 or 
a NextSeq500 machine (Illumina, San Diego, CA) with 2 x 100 bp and 2 x 150 bp paired-end 
reads, respectively, at an average coverage of 100 x and with >90% of the exome covered 
>20x. Sequence reads were aligned to the human reference genome GRCh37/hg19 with 
the Burrows-Wheeler Aligner version 0.7.5a.22 Variants were called using Genome Analysis 
Toolkit (GATK) software.23,24 For two patients (F6P1 and F26P1), whole-genome sequencing 
(WGS) was performed to avoid time-consuming capturing steps because of their severe 
clinical conditions and young age, as described previously25 (Supplementary Materials 
and methods).
A gene list of 310 genes was created based on the HPO term cardiomyopathy (HP:0001638; 
http://www.human-phenotype-ontology.org/), supplemented with genes not included in this 
HPO term but associated with CM in recent scientific reports26 (Supplemental Table 4). To 
generate a ‘private’ gene panel, this gene list was expanded with genes assigned to other 
HPO terms for individual patients when appropriate (Supplemental Table 5). In order to 
define the most relevant HPO terms, a clinical geneticist discussed the patients’ phenotypes 
with a paediatric cardiologist, a paediatrician, a neurologist, and/or other relevant physicians.
Potentially relevant variants were evaluated in a multidisciplinary meeting with at least a clinical 
geneticist, a molecular geneticist, and a laboratory technician present. When necessary, a 
cardiologist, neurologist and/or paediatrician were also consulted. An independent expert panel 
was set up to discuss the clinical relevance of IFs, predefined as likely or definitely pathogenic 
variants in known disease genes unrelated to the patient’s current phenotype, as described 
elsewhere.25
Calculation of internal and potential diagnostic yield
The internal yield was calculated as the number of families in which a genetic diagnosis was found 
divided by the total number of families subjected to CNV analysis and ES. Since we excluded 13 
families whose genetic diagnosis had been established by other techniques (multiplex ligation-
dependent probe amplification (MLPA), Sanger sequencing, or targeted NGS), the internal yield 
is an underestimation of the yield in an unselected cohort. To adjust for this, these 13 families 
were included in our analysis retrospectively.
More than 50% diagnostic yield in paediatric DCM cases
87
4
The potential yield, assuming that all 85 families were offered ES/CNV analysis as routine genetic 
testing, was estimated as the internal yield plus a proportion of the 13 families who were not 
included initially (because in this group too, a subset of patients may not respond to the invitation 
or may refrain from further testing). We applied a correction factor of 0.43 (proportion of 
families subjected to ES/SNP array divided by the total number of families eligible for ES/CNV 





The clinical and genetic results for all 35 patients are summarized in Tables 1-3 and Supplemental 
Tables 1, 2 and 6.
Subjects and clinical characteristics
Figure 1 depicts the study setup. After excluding 16 patients (13 families) who already had 
a genetic diagnosis that explained their phenotype and young age at onset (Supplemental 
Table 1), we identified 79 patients from 72 families that fulfilled our inclusion criteria. For 19 
families, either no DNA or tissue for a deceased patient was available for testing or it was not 
feasible to inform patients/families about new diagnostic possibilities (i.e. NGS); another 14 
patients (14 families) did not respond to the invitation, and 9 patients (8 families) refrained from 
further testing. We performed trio-based ES (WGS in two) and CNV analysis in 31 unrelated 
families (31 probands and 4 siblings in total; patient characteristics are shown in Table 1 and 
Supplemental Table 2).
Internal yield
A genetic diagnosis could be made in 15 of 31 families (48.4%, 95% CI: 30.2-66.9%) (Table 2). 
In 14 families (45.2%), the identified genetic defect could explain their DCM. The mutation in 
the 15th family has not been associated with DCM so far, but it does explain additional clinical 
features seen in the patient (see also below and Supplementary Data 2). Exome sequencing 
yielded a diagnosis in 13/15 families (86.7%). Except for one, these pathogenic or likely 
pathogenic variants were identified in eight CM-associated genes. Ten of the 13 variants (76.9%) 
were heterozygous and found in genes encoding structural components of cardiomyocytes, two 
of these were de novo (Table 2).
In 2/13 (15.4%) families diagnosed by ES, we identified causal variants in less well-known CM 
genes: one homozygous variant in the beta-1 galactosidase (GLB1) gene and one homozygous 
variant in the SPEG complex locus (SPEG) gene. In one patient (F6P1) carrying the GLB1 
mutation, we found an additional likely pathogenic variant in the T-box 20 (TBX20) gene. The 
probands in both these families had consanguineous parents and showed extracardiac features 
(Table 2).
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All patients  
N = 95 (85 families) 
N = 79 (72 families) 
Known genetic diagnosis  
N = 16 (13 families) 
Patients we could not inform 
about new diagnostic 
possibilities  
N = 21 (19 families) 
Patients that were subjected to 
ES/SNP array 
N = 35 (31 families) 
No response  
N = 14 (14 families) 
Patients who refrained from 
further testing  
N = 9 (8 families) 
Diagnosis made by  
ES/SNP array  
N = 18 (15 families) 
No diagnosis made by ES/SNP 
array  
N = 17 (16 families) 
Diagnoses that WOULD 
potentially be made by ES/SNP 
array  
N = 14 (11 families) 
Diagnoses that would NOT be 
made by ES/SNP array  
N = 2 (2 families) 
Patients with characteristic 
features of mitochondrial 
disorders mtDNA analysis N = 2 
(2 families) 
Patients not included  
N = 44 (41 families) 
Patients without characteristic 
features of mitochondrial 
disorders 
N = 14 (13 families) 
Figure 1. Study profile and diagnostic yield. We could not reach or test 19 families because, for example, 
an address was unavailable or the patient had died and no DNA/tissue was available. Of the 72 families 
who initially had no genetic diagnosis, 31 (43%) were subjected to ES/CNV analysis. Characteristic 
features of mitochondrial disease were reviewed by Leonard and Schapira.40 ES/CNV=exome sequencing/
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Prodromal symptoms 13/35 37.1%














Features of LVNC identified during follow-up or at postmortem investigation 4/35 11.4%
Extracardiac features 16/35 45.7%
Consanguineous parents 5/31 16.1%
Positive family history for cardiomyopathy 7/16 43.8%
Cardiac screening was advised for first-degree relatives in 26 families, and relatives of at least 16 index 
patients underwent electrocardiography and echocardiography. CNV=copy-number variation, ES/
WGS=exome sequencing/whole-genome sequencing, HtX=heart transplantation, LVAD=left ventricular 
assist device, LVNC= left ventricular noncompaction.
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Expanding our virtual gene panel by adding HPO terms to the filtering tree in patients with 
additional features identified compound heterozygous variants c.874C>T, p.(Arg292*) and 
c.3118_3121delAACA, p.(Asn1040Glufs*9) in CEP135 in patient F25P1. These explain her 
microcephaly and developmental delay, but it is unclear whether they also explain her DCM (for 
further discussion, see Supplementary Data).
In addition to the 13 families diagnosed by ES, two diagnoses were made by SNP array (2/15; 
13.3%, Table 2). In patient F29P1, who presented with a severe dilated left ventricle, several 
apical VSDs, and an open ductus arteriosus at age 2 weeks, a de novo 1p36.33p36.32 deletion 
was identified consistent with chromosome 1p36 deletion syndrome (MIM607872). In patient 
F31P1, who presented with decompensated heart failure at age 16 years, a de novo 10q25.2 
deletion was identified encompassing the RNA-binding motif protein 20 (RBM20) gene. A 
deletion including this gene has not been described before, although RBM20 missense variants 
have been associated with early-onset DCM, end-stage heart failure, and high mortality;27 
several studies suggest a loss-of-function effect.28,29 
Importantly, we determined a genetic diagnosis for 6/13 patients (46.1%) with possible acute 
myocarditis. Although they did not meet the Dallas criteria30, they suffered from prodromal 
symptoms mimicking a viral infection, including abdominal pain, vomiting, upper respiratory 




Table 2. Paediatric DCM patients analysed with trio-exome sequencing and SNP array, with a genetic 
diagnosis.
ID Cardiac phenotype HPO terms Trio-exome sequencing SNP array
F1P1 DCM with features of LVNC 
Dysplastic tricuspid valve
Cardiomyopathy (HP:0001638)
Abnormality of the tricuspid valve (HP:0001702)
MYH7 (NM_000257.2) c.3113T>C, p.(Leu1038Pro), pat (P)
GYS1 (NM_002103.4) c.1204delA, p.(Arg402Glyfs*15), pat (AR) (P)
Normal
F1P2 DCM with features of LVNC
Dysplastic tricuspid valve
Cardiomyopathy (HP:0001638)
Abnormality of the tricuspid valve (HP:0001702)
MYH7 (NM_000257.2) c.3113T>C, p.(Leu1038Pro), pat (P)
RBM20 (NM_001134363.1) c.2042A>G, p.(Tyr681Cys), pat
NP
F2P1 DCM Cardiomyopathy (HP:0001638) TNNT2 (NM_001276347.1) c.629_631delAGA, p.(Lys210del), de novo (P)
CSRP3 (NM_003476.4) c.85A>G, p.(Ser29Gly), mat
PTPN11 (NM_002834.3) c.455G>A, p.(Arg152His), pat
Normal
F3P1 DCM Cardiomyopathy (HP:0001638) MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys), mat (P)
TTN (NM_001267550.1) c.62710T>C, p.(Cys20904Arg), mat
NP
F3P2 DCM Cardiomyopathy (HP:0001638) MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys), mat (P)
MYH7 (NM_000257.2) c.328G>A, p.(Gly110Ser), pat
SYNE1 (NM_182961.3) c.18727G>A, p.(Glu6243Lys), mat
FHL1 (NM_001159702.2) 968C>T, p.(Pro323Leu), mat
NP
F3P3 DCM Cardiomyopathy (HP:0001638) MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys), pat (P) NP
F4P1 DCM Cardiomyopathy (HP:0001638)
Multifocal atrial tachycardia (HP:0011701)
Supraventricular tachycardia (HP:004755)
SCN5A (NM_001099404.1) c.2512G>A, p.(Ala838Thr), mat (LP)
RAB3GAP2 (NM_012414.3) c.1613C>T, p.(Pro538Leu), mat
POLG (NM_002693.2) c.2542G>A, p.(Gly848Ser), mat
TNNC1 (NM_003280.2) c.304C>T, p.(Arg102Cys), pat
LDB3 (NM_007078.2) c.1051A>G, p.(Thr351Ala), pat
MYH6 (NM_002471.3) c.4193G>A, p.(Arg1398Gln), pat
ANKRD11 (NM_001256182.1) c.244C>T, p.(Arg82Trp), pat
DTNA (NM_001198939.1) c.153C>G, p.(His51Gln), pat
DTNA (NM_001198939.1) c.239G>A, p.(Arg80His), pat
Normal
F5P1 DCM Cardiomyopathy (HP:0001638)
Leukopenia (HP:0001882)
Inflammation of the large intestine (HP:0002037)
Hyperammonemia (HP:0001987)
TTN (NM_001267550.1) c.89314G>T, p.(Glu29772*), pat (LP)
SGSH (NM_000199.3) c.892T>C, p.(Ser298Pro) (AR) (P)
CPS1 (NM_001875.4) c.295C>A, p.(Pro99Thr)
WFS1 (NM_006005.3) c.605A>G, p.(Glu202Gly)
SYNE2 (NM_182914.2) c.20039G>A, p.(Arg6680Gln)
PLEKHM2 (NM_015164) c.820G>A, p.(Glu274Lys)
Dup1q21.1q21.2 (2.0 Mb)
Del 5q31.3 (178.0 Kb)
More than 50% diagnostic yield in paediatric DCM cases
93
4
Table 2. Paediatric DCM patients analysed with trio-exome sequencing and SNP array, with a genetic 
diagnosis.
ID Cardiac phenotype HPO terms Trio-exome sequencing SNP array
F1P1 DCM with features of LVNC 
Dysplastic tricuspid valve
Cardiomyopathy (HP:0001638)
Abnormality of the tricuspid valve (HP:0001702)
MYH7 (NM_000257.2) c.3113T>C, p.(Leu1038Pro), pat (P)
GYS1 (NM_002103.4) c.1204delA, p.(Arg402Glyfs*15), pat (AR) (P)
Normal
F1P2 DCM with features of LVNC
Dysplastic tricuspid valve
Cardiomyopathy (HP:0001638)
Abnormality of the tricuspid valve (HP:0001702)
MYH7 (NM_000257.2) c.3113T>C, p.(Leu1038Pro), pat (P)
RBM20 (NM_001134363.1) c.2042A>G, p.(Tyr681Cys), pat
NP
F2P1 DCM Cardiomyopathy (HP:0001638) TNNT2 (NM_001276347.1) c.629_631delAGA, p.(Lys210del), de novo (P)
CSRP3 (NM_003476.4) c.85A>G, p.(Ser29Gly), mat
PTPN11 (NM_002834.3) c.455G>A, p.(Arg152His), pat
Normal
F3P1 DCM Cardiomyopathy (HP:0001638) MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys), mat (P)
TTN (NM_001267550.1) c.62710T>C, p.(Cys20904Arg), mat
NP
F3P2 DCM Cardiomyopathy (HP:0001638) MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys), mat (P)
MYH7 (NM_000257.2) c.328G>A, p.(Gly110Ser), pat
SYNE1 (NM_182961.3) c.18727G>A, p.(Glu6243Lys), mat
FHL1 (NM_001159702.2) 968C>T, p.(Pro323Leu), mat
NP
F3P3 DCM Cardiomyopathy (HP:0001638) MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys), pat (P) NP
F4P1 DCM Cardiomyopathy (HP:0001638)
Multifocal atrial tachycardia (HP:0011701)
Supraventricular tachycardia (HP:004755)
SCN5A (NM_001099404.1) c.2512G>A, p.(Ala838Thr), mat (LP)
RAB3GAP2 (NM_012414.3) c.1613C>T, p.(Pro538Leu), mat
POLG (NM_002693.2) c.2542G>A, p.(Gly848Ser), mat
TNNC1 (NM_003280.2) c.304C>T, p.(Arg102Cys), pat
LDB3 (NM_007078.2) c.1051A>G, p.(Thr351Ala), pat
MYH6 (NM_002471.3) c.4193G>A, p.(Arg1398Gln), pat
ANKRD11 (NM_001256182.1) c.244C>T, p.(Arg82Trp), pat
DTNA (NM_001198939.1) c.153C>G, p.(His51Gln), pat
DTNA (NM_001198939.1) c.239G>A, p.(Arg80His), pat
Normal
F5P1 DCM Cardiomyopathy (HP:0001638)
Leukopenia (HP:0001882)
Inflammation of the large intestine (HP:0002037)
Hyperammonemia (HP:0001987)
TTN (NM_001267550.1) c.89314G>T, p.(Glu29772*), pat (LP)
SGSH (NM_000199.3) c.892T>C, p.(Ser298Pro) (AR) (P)
CPS1 (NM_001875.4) c.295C>A, p.(Pro99Thr)
WFS1 (NM_006005.3) c.605A>G, p.(Glu202Gly)
SYNE2 (NM_182914.2) c.20039G>A, p.(Arg6680Gln)
PLEKHM2 (NM_015164) c.820G>A, p.(Glu274Lys)
Dup1q21.1q21.2 (2.0 Mb)




ID Cardiac phenotype HPO terms Trio-exome sequencing SNP array
F6P1* DCM Cardiomyopathy (HP:0001638)
Hepatomegaly (HP:0002240)
Right ventricular failure (HP:0001708)
GLB1 (NM_000404.2) c.176G>A, p.(Arg59His) (homozygous), pat, mat* 
(P)
TBX20 (NM_001077653.2) c.456C>G, p.(Ile152Met) (LP)
MYBPC3 (NM_000256.3) c.194C>T, p.(Thr65Met)
MYH6 (NM_002471.3) c.4037G>A, p.(Arg1346Gln)
RAF1 (NM_002880.3) c.29C>T, p.(Thr10Met)
LIAS (NM_006859.3) c.1114C>A, p.(Leu372Ile)
ABCB4 (NM_018849.2) c.3829G>T, p.(Val1277Phe)
SERPINA1 (NM_001127701.1) c.936A>T, p.(Leu312Phe)
SERPINA1 (NM_001127701.1) c.952A>T, p.(Thr318Ser)
FANCA (NM_001286167.1) c.871A>G, p.(Thr291Ala)
PTRF (NM_012232.5) c.7G>A, p.(Asp3Asn)
SDHAF1 (NM_001042631.2) c.334C>T, p.(Pro112Ser)
XIAP (NM_001167.3) c.838A>C, p.(Asn280His)
10 homozygous regions > 
10 Mb
F7P1 DCM Cardiomyopathy (HP:0001638) 
Myopathy (HP:0003198)
SPEG (NM_005876) c.9185_9187delTGG; p.(Val3062del) (homozygous) 
(P)






TPM1 (NM_001018004.1) c.475G>A, p.(Asp159Asn), de novo (P)
MYPN (NM_032578.3) c.416_412delinsTGG, p.(Gln139_
Cys141delinsLeuGly), pat
PDE11A (NM_016953.3) c.919C>T p.(Arg307*), mat
NEBL (NM_006393.2) c.1715C>T, p.(Ser572Phe), pat
COQ4 (NM_016035.4) c.653delT, p.(Leu218*), mat (AR)
Normal
F9P1 DCM Cardiomyopathy (HP:0001638)
Hypertension (HP:0000822)
MYH7 (NM_000257.2) c.3100-2A>C, pat (LP)
PEX1 (NM_000466.2) c.2528G>A, p.(Gly843Asp), mat (AR) (P)
FHL2 (NM_201555.1) c.487_488delGT, p.(Val163Serfs*42), mat
DSP (NM_004415.2) c.8300C>G, p.(Thr2767Ser), pat 
Normal
F10P1 DCM Cardiomyopathy (HP:0001638) 
Abnormality of metabolism/homeostasis 
(HP:0001939)
MYL2 (NM_000432.3) c.263A>C, p.(Glu88Ala) (LP)
TMPO (NM_001032283.2) c.232G>C, p.(Gly78Arg)
PCCA (NM_000282.3) c.1896A>G, p.(=)
FKBP10 (NM_021939.3) c.210C>G, p.(Asn70Lys)





Abnormality of the heart valves (HP:0001654)
MYL2 (NM_000432.3) c.263A>C, p.(Glu88Ala), mat (LP) Normal
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DMD (NM_004006.2) c.1536C>A, p.(His512Gln), mat
PCCA (NM_000282.3) c.1289G>A, p.(Arg430Gln), mat
PCCB (NM_001178014.1) c.875G>A, p.(Arg292Gln), mat
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ID Cardiac phenotype HPO terms Trio-exome sequencing SNP array
F6P1* DCM Cardiomyopathy (HP:0001638)
Hepatomegaly (HP:0002240)
Right ventricular failure (HP:0001708)
GLB1 (NM_000404.2) c.176G>A, p.(Arg59His) (homozygous), pat, mat* 
(P)
TBX20 (NM_001077653.2) c.456C>G, p.(Ile152Met) (LP)
MYBPC3 (NM_000256.3) c.194C>T, p.(Thr65Met)
MYH6 (NM_002471.3) c.4037G>A, p.(Arg1346Gln)
RAF1 (NM_002880.3) c.29C>T, p.(Thr10Met)
LIAS (NM_006859.3) c.1114C>A, p.(Leu372Ile)
ABCB4 (NM_018849.2) c.3829G>T, p.(Val1277Phe)
SERPINA1 (NM_001127701.1) c.936A>T, p.(Leu312Phe)
SERPINA1 (NM_001127701.1) c.952A>T, p.(Thr318Ser)
FANCA (NM_001286167.1) c.871A>G, p.(Thr291Ala)
PTRF (NM_012232.5) c.7G>A, p.(Asp3Asn)
SDHAF1 (NM_001042631.2) c.334C>T, p.(Pro112Ser)
XIAP (NM_001167.3) c.838A>C, p.(Asn280His)
10 homozygous regions > 
10 Mb
F7P1 DCM Cardiomyopathy (HP:0001638) 
Myopathy (HP:0003198)
SPEG (NM_005876) c.9185_9187delTGG; p.(Val3062del) (homozygous) 
(P)






TPM1 (NM_001018004.1) c.475G>A, p.(Asp159Asn), de novo (P)
MYPN (NM_032578.3) c.416_412delinsTGG, p.(Gln139_
Cys141delinsLeuGly), pat
PDE11A (NM_016953.3) c.919C>T p.(Arg307*), mat
NEBL (NM_006393.2) c.1715C>T, p.(Ser572Phe), pat
COQ4 (NM_016035.4) c.653delT, p.(Leu218*), mat (AR)
Normal
F9P1 DCM Cardiomyopathy (HP:0001638)
Hypertension (HP:0000822)
MYH7 (NM_000257.2) c.3100-2A>C, pat (LP)
PEX1 (NM_000466.2) c.2528G>A, p.(Gly843Asp), mat (AR) (P)
FHL2 (NM_201555.1) c.487_488delGT, p.(Val163Serfs*42), mat
DSP (NM_004415.2) c.8300C>G, p.(Thr2767Ser), pat 
Normal
F10P1 DCM Cardiomyopathy (HP:0001638) 
Abnormality of metabolism/homeostasis 
(HP:0001939)
MYL2 (NM_000432.3) c.263A>C, p.(Glu88Ala) (LP)
TMPO (NM_001032283.2) c.232G>C, p.(Gly78Arg)
PCCA (NM_000282.3) c.1896A>G, p.(=)
FKBP10 (NM_021939.3) c.210C>G, p.(Asn70Lys)





Abnormality of the heart valves (HP:0001654)
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PCCA (NM_000282.3) c.1289G>A, p.(Arg430Gln), mat











Cardiomyopathy (HP:0001638) FLNC (NM_001458) c.1673G>A, p.(Arg558His)
SPEG (NM_005876.4) c.4822G>A, p.(Gly1608Ser)
TTN (NM_001267550.2) c.103879G>C, p.(Asp34627His)
Del 1p36.33p36.32 (3,6 
Mb), de novo (P)
F30P1 DCM Cardiomyopathy (HP:0001638) MYH7 (NM_000257.2) c.1633G>A p.(Asp545Asn) and c.2863G>A 
p.(Asp955Asn) in cis, pat (P)
Normal
F31P1 DCM with features of LVNC Cardiomyopathy (HP:0001638) Negative Del 10q25.2 (204.4 Kb), 
de novo (P)
Variants classified as pathogenic (P) or likely pathogenic (LP) are indicated in bold, other variants are 
classified as of unknown significance (VUS). Ten of the 13 variants (76.9%) were heterozygous and found 
in genes encoding structural components of cardiomyocytes: one in cardiac troponin T2 (TNNT2), one 
in sodium channel, voltage gated, type V, alpha (SCN5A), one in titin (TTN), one in alpha tropomyosin 1 
(TPM1), two in regulatory light chain-2 of myosin (MYL2), and four in the cardiac beta-myosin heavy chain 
7 (MYH7) gene. Two of these were de novo variants, c.629_631delAGA, p.(Lys201del) in TNNT2 and 
c.475G>A, p.(Asp159Asn) in TPM1. We identified no genomic deletion harbouring autosomal recessive 
(AR) disease genes on the other allele in any patients who carried a heterozygous pathogenic AR disease 
mutation. 
DCM=dilated cardiomyopathy, del=deletion, dup=duplication, F1P1=family 1 - patient 1, HPO=Human 
Phenotype Ontology, LVH=left ventricular hypertrophy, LVNC=left ventricular noncompaction, 
mat=maternal, NP=not performed, pat=paternal, PDA=patent ductus arteriosus, SNP=single-nucleotide 
polymorphism, VSD=ventricular septal defect.
*In patient F6P1, who carried a homozygous GLB1 mutation, we confirmed GM1 gangliosidosis by 
β-galactosidase enzyme analysis in peripheral blood leukocytes (1% residual activity). 
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Table 3. Paediatric DCM patients analysed with trio-exome sequencing and SNP array, without a 
genetic diagnosis to explain their DCM.
ID Cardiac phenotype HPO terms Result SNP array
F11P1 DCM Cardiomyopathy (HP:0001638) PRDM16 (NM_022114) c.1882G>A, p.(Asp628Asn) Dup 20p12.3-p12.2 (512 Kb), 
mat
F12P1 DCM Cardiomyopathy (HP:0001638)
Arrhythmia (HP:0011675)
TERT (NM_198253.2) c.1323_1325delGGA, p.(Glu441del), mat
KCNH2 (NM_000238.3) c.3052C>G, p.(Pro1018Ala), mat
NP
F13P1 DCM with restrictive component
Recently revised as constrictive 
pericarditis
Cardiomyopathy (HP:0001638) GSN (NM_000177.4) c.130dupG, p.(Val44Glyfs*68), mat 
KRAS (NM_033360.2) c.540T>A, p.(Cys180*), pat
DMD (NM_004006.2) c.3816G>C, p.(Leu1272Phe), mat 
Normal
F15P1 DCM Cardiomyopathy (HP:0001638) SYNE1 (NM_182961.3) c.25381G>A, p.(Glu8461Lys), pat
SYNE1 (NM_182961.3) c.26165G>A, p.(Gly8722Asp), pat
RYR2 (NM_001035.2) c.14757-7_14757-6delinsAT, pat
SCN5A (NM_001099404.1) c.2924G>A, p.(Arg975Gln), mat
NDUFA11 (NM_001193375.1) c.685T>C, p.(*229Argext*21), mat
Normal
F16P1 DCM Cardiomyopathy (HP:0001638) TNNT2 (NM_001276347.1) c.522G>C, p.(Lys174Asn), mat
FLNC (NM_001458) c.5791C>T, p.(Arg1931Cys), pat
Dup 4q35.2 (666 Kb)





Abnormality of the kidney (HP:0000077)
Abnormality of the cardiac septa (HP:001671) 
TNNT2 (NM_001276347.1) c.522G>C, p.(Lys174Asn), mat 
APC (NM_000038.5) c.4625C>G, p.(Pro1542Arg), mat 
SYNE1 (NM_182961.3) c.6589T>C, p.(Ser2197Pro), mat 
OCA2 (NM_000275.2) c.1327G>A, p.(Val443Ile), mat
SLC26A4 (NM_000441.1) c.2235G>A, p.(=), de novo 
CTNNA3 (NM_013266) c.2314A>G, p.(Ile772Val), mat
Several homozygous regions > 
3 Mb
F17P1 SCD




PMM2 (NM_000303.2) c.422G>A, p.(Arg141His), mat (AR)
DPYD (NM_000110.3) c.557A>G, p.(Tyr186Cys), pat 
NDUFA10 (NM_004544.3) c.332A>G, p.(Asn111Ser), pat 
NDUFA10 (NM_004544.3) c.506T>C, p.(Phe169Ser), mat 
SCN5A (NM_001099404.1) c.5860G>A, p.(Glu1954Lys), pat
Normal
F18P1 DCM Cardiomyopathy (HP:0001638) LDB3 (NM_001171610) c.676G>A, p.(Gly226Arg), pat Normal
F19P1 DCM Cardiomyopathy (HP:0001638) DTNA (NM_001392.4) c.*5A>G, mat, pat NP
F20P1 DCM Cardiomyopathy (HP:0001638)
Arrhythmia (HP:0011675) 
SDHA (NM_001294332.1) c.544G>C, p.(Glu182Gln), pat
ERCC6 (NM_000124.2) c.1670G>A, p.(Arg557His), pat
NP
F21P1 DCM Cardiomyopathy (HP:0001638) TTN (NM_001267550.1) c.98119G>C, p.(Asp32707His), mat
TTN (NM_001267550.1) c.11996A>G, p.(Asn3999Ser), mat
PLEC (NM_201380.3) c.8321C>T, p.(Ala2774Val), mat 
PLEC (NM _201380.3) c.10964A>G, p.(His3655Arg), pat





Hypoplastic left heart (HP:0004383)
Congenital malformation of the left heart 
(HP:00045017)
NDUFS4 (NM_002495.2) c.278A>G, p.(Asn93Ser), mat 
DSG2 (NM_001943.3) c.2623A>G, p.(Met875Val) , pat
Del 1q44 (323.9 Kb)
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F19P1 DCM Cardiomyopathy (HP:0001638) DTNA (NM_001392.4) c.*5A>G, mat, pat NP
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Hypoplastic left heart (HP:0004383)
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ID Cardiac phenotype HPO terms Result SNP array
F23P1 DCM with LVH Cardiomyopathy (HP:0001638)
Seizures (HP:0001250)
TTN (NM_001267550.1) c.35189_35191delAAG, 
p.(Glu11730del), pat 





Cardiomyopathy (HP:0001638) ANKRD11 (NM_001256182.1) c.2880G>C, p.(Glu960Asp), pat
TTN (NM_001267550.1) c.51443C>G, p.(Pro17148Arg), mat
Del 17q21.31 (676 Kb), de novo 
(P) - Koolen-de Vries syndrome 
(OMIM #610443)
F26P1 DCM Cardiomyopathy (HP:0001638) TTN (NM_001267550.1) c.13048G>A, p.(Val4350Met)
JUP (NM_002230.2) c.1571T>C, p.(Ile524Thr)
Normal
F27P1 DCM Cardiomyopathy (HP:0001638) RAB3GAP2 (NM_012414.3) c.683_684delTT, 
p.(Leu228Profs*16), pat (AR)
TTN (NM_001267550.1) c.55355C>G, p.(Ser18452Cys), pat
TTN (NM_001267550.1) c.43700G>C, p.(Arg14567Thr), pat
COL7A1 (NM_000094.3) c.6977C>A, p.(Pro2326Gln), pat
POLG (NM_002693.2) c.3064C>G, p.(Leu1022Val), mat
EPG5 (NM_020964.2) c.4169A>G, p.(Tyr1390Cys), pat
Normal
F28P1 DCM Cardiomyopathy (HP:0001638) RBM20 (NM_001134363.2) c.2042A>G, p.(Tyr681Cys), pat Normal
Variants classified as definitely pathogenic (P) or likely pathogenic (LP) are indicated in bold, other variants 
are classified as of unknown significance (VUS). 
AR=autosomal recessive, ASD=atrial septal defect, DCM=dilated cardiomyopathy, del=deletion, 
dup=duplication, HLHS=hypoplastic left heart syndrome, HPO=human phenotype ontology, LVH=left 
ventricular hypertrophy, LVNC=left ventricular noncompaction, mat=maternal, NCCM=noncompaction 
cardiomyopathy, NP= not performed, pat=paternal, RVH=right ventricular hypertrophy, SCD=sudden 
cardiac death, SNP=single-nucleotide polymorphism, VSD=ventricular septal defect.
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Because we excluded patients with a known genetic diagnosis, our overall diagnostic yield is an 
underestimation. To compensate, we included these families retrospectively and calculated the 
potential yield. If we had included the 13 families who were initially excluded, the estimated yield 
would have been 53.9% (95% CI: 37.4-68.7%) (Figure 2).
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Figure 2. Our proposed stepwise diagnostic approach for analysing paediatric DCM patients and the 
resulting internal and potential yields. Step 1. Analysis of a limited selection of 60 genes, encoding mostly 
structural components of cardiomyocytes. Step 2. CNV analysis, including homozygosity analysis. Step 3. 
Reanalysis of the data by filtering for variants in a comprehensive virtual gene panel, based on the HPO term 
“cardiomyopathy”. Step 4. Adding more HPO terms for filtering in those patients presenting with additional 
cardiac and/or noncardiac features. In the group without a diagnosis, 43% (31/72 families) agreed to undergo 
ES and CNV analysis. We reasoned that the group of 16 patients (from 13 families, Supplemental Table 1) with 
a known genetic diagnosis, to whom we did not offer ES/CNV analysis, would not differ much from the group 
that was eligible for ES/CNV analysis (e.g., no bias in severity of DCM or number of familial cases). Therefore, 
the same percentage of inclusions should also be applicable to this ‘not offered ES/CNV analysis’ group. Eleven 
of these 13 families would have been identified by our approach if ES/CNV analysis had been performed as the 
first-tier test. The potential yield would therefore be the sum of the internal yield (15/31 families) plus the 0.43 
proportion of the excluded patients who already had a genetic diagnosis (15+(11*0.43))/(31+(13*0.43)), which 
is 53.9%. CM=cardiomyopathy, CNV=copy-number variation, DCM=dilated cardiomyopathy, ES=exome 
sequencing, HPO=Human Phenotype Ontology, SNP=single-nucleotide polymorphism, VUS=variant of 
unknown significance, WES= whole-exome sequencing.
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Variants of unknown significance
We identified up to 11 VUS per patient (n = 96, mean 2.74 per patient), including 5 chromosomal 
CNVs (Tables 2 and 3). During our study, the MYL2 c.263A>C, p.(Glu88Ala) variant (identified in 
two patients) was reclassified as likely pathogenic, based on segregation analysis in three families 
and the identification of a common haplotype (Supplementary Data 1 and Supplemental 
Figure 1).
Incidental findings
No IFs in AD inherited disease genes were found. A pathogenic variant in AR inherited disease 
genes was identified in 5 of the 35 patients (14.3%) (Tables 2 and 3): in GYS1 (Glycogen storage 
disease 0, muscle, OMIM 138570), in SGSH (Mucopolysaccharidosis type IIIA, OMIM 252900), 
in PEX1 (peroxisome biogenesis disorder 1A, OMIM 214100), in PMM2 (congenital disorder 
of glycosylation type Ia, OMIM 212065), and in RAB3GAP2 (Warburg micro syndrome 2, 
OMIM 614225; Martsolf syndrome, OMIM 212720). None of the patients’ phenotypes fits 
the respective disease, and the carrier frequency of a disease-causing mutation in each of the 
five genes is <1/60. 
Toward the most effective analysis strategy
Based on our results, we retrospectively tested a stepwise analysis on our data. To determine 
the most effective approach for genetic testing and data analysis, leading to the highest increase 
in yield at each subsequent diagnostic step, we also included the patients who already had a 
diagnosis. Most such genetic diagnoses would have been made by analysing only a limited 
selection of well-known CM genes (35.6%; 95% CI: 22.7-53.0%) (Figure 2, step 1). Subsequently, 
adding CNV analysis would have resulted in an increase in diagnostic yield to 44.6% (95% CI: 
29.9-61.1%) (Figure 2, step 2). Finally, filtering the data by generating a virtual gene panel based 
on the HPO term cardiomyopathy (HP:0001638) in the patients still without a genetic diagnosis 
and subsequently adding more HPO terms, where appropriate, would have led to an increase 
of up to 51.2% (95% CI: 34.8-66.2%) and 53.9% (95% CI: 37.4-68.7 %) diagnoses, respectively.
The numbers of VUS identified per step are shown in Figure 2. We only encountered carriers 




Paediatric DCM is a relatively rare but life-threatening disease with a strong genetic component. 
Genetic testing improves its clinical management and has become an essential part of contemporary 
care for children with DCM and their families. NGS technology offers excellent opportunities for 
efficient genetic diagnostics in general, but little has been reported for paediatric DCM. We had a 
relatively large cohort of unselected, well-phenotyped patients that provided a unique opportunity 
to implement and test the efficacy of an approach involving CNV analysis and trio-based ES with 
analysis of a virtual gene panel of more than 310 CM-related genes. The use of HPO terms for 
data filtering has major advantages over a fixed gene panel as they are automatically updated 
and patient-specific terms can be used. Testing 31 probands with DCM and their parents, our 
approach yielded a diagnosis in 48.4% (15/31). Applying this approach retrospectively to all our 
cases, including those who already had a genetic diagnosis, would have resulted in a yield > 50%.
We have also shown that the same genetic workup is justified in patients with possible myocarditis 
and childhood cancer survivors in whom DCM presents as a toxic side effect. The high yield 
obtained with our approach also holds an important implication: that in many cases, a ‘genetics-
first’ approach can reduce or even avoid costly intensive care for some children (e.g., F6P1 and 
F29P1) or replace other time-consuming and/or invasive, nongenetic diagnostic testing (e.g., 
F7P1). Moreover, a prospective study by Stark et al.31 showed that ES used early in the diagnostic 
pathway more than triples the diagnostic rate for one-third of the cost per diagnosis.
Stepwise diagnostic approach
To reduce the analytic effort, the number of VUS, the cost and the chance of identifying IFs, 
we now propose a standardized, stepwise analysis of a subset of genomic data in paediatric 
DCM cases (Figure 2). We prioritized the diagnostic steps according to the highest increase 
in yield per step. We do not claim that this strategy provides the best or quickest analytical 
path in general; rather, it represents an ad hoc approach inferred from our current results. The 
generalizability of our stepwise approach needs to be corroborated in larger cohorts, which 
also may lead to obtain greater insight into the meaning of variants in genes that are less often 
associated with CM.
Our study shows that restricting the analysis to genes encoding desmosomal cell adhesion 
proteins, sarcomeric proteins, and a few other, well-established CM genes (n = 60), would 
potentially yield a diagnosis in 35.6% of paediatric patients. This is slightly lower than the 
37% yield in a paediatric cohort reported by Rampersaud et al.18 However, they included 
predominantly familial DCM (85% of cases), whereas we included both familial cases (23%) and 
patients with a negative family history for CM (77%), although cardiac screening was performed 
in most, but not all, first-degree relatives.
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The addition of a CNV analysis would increase our potential yield to 44.6%. This rise can be 
explained by the relatively high percentage of patients diagnosed with Duchenne Muscular 
Dystrophy (Supplemental Table 1) who carry a deletion/duplication of (at least) the DMD gene.
Finally, reanalysing the data by filtering for variants in a comprehensive, but personalized, virtual 
gene panel based on HPO cardiomyopathy, plus additional HPO terms where appropriate, 
would have resulted in a total diagnostic potential of 51.2% and 53.9%, respectively (Figure 2, 
steps 3 and 4). Therefore, the presence/absence of syndromic or extracardiac features should 
indicate the extent of genetic analysis required in a clinical setting. The use of HPO terms and 
stepwise data analysis reduces the number of VUS and the chance of identifying IFs, which is 
in accordance with current guidelines for genetic testing in minors32 and more specifically for 
DCM.19
Pros and cons of our ES-based approach
Currently, the strategies for NGS of patients with CM can be divided into two fundamentally 
different approaches: targeted gene panel sequencing, with capture of a restricted set of genes, 
and ES/WGS. The pros and cons of these approaches for other patient categories have been 
extensively reviewed.33 Our approach combines the following advantages of both methods 
(for related examples from our cohort, see Supplementary Data 2). (1)  Although ES data 
interpretation is, in general, more complicated and time-consuming than targeted gene panel 
sequencing, using virtual gene panels to filter ES data reduces the number of genetic variants 
needing to be interpreted. Moreover, by filtering for variants in the genes of interest, the number 
of IFs and VUS is reduced. (2) In consanguineous families, variant filtering may first be restricted 
to homozygous regions. (3) Multiple relevant variants in one patient can be detected.18,34-36 (4) 
Novel traits may be identified by using additional HPO terms. (5) Our filter strategy can be 
applied to all cardiomyopathies that show clinical and genetic overlap and that are sometimes 
difficult to classify on echocardiographic parameters. (6) Having the full exome available offers 
the option to broaden the analysis if a diagnosis cannot be made and/or if clinical development 
indicates that other approaches are needed. This may involve alternative filtering or “opening” 
the exome, which could lead to identification of novel genes associated with paediatric CM, as 
we recently showed for ALPK3.37
However, an ES-based diagnostic approach also has some disadvantages: (1) A potentially 
lower vertical coverage of some regions compared to targeted gene panel sequencing may 
lead to some mutations being missed, although LaDuca et al. showed that ES covered 99.6% 
of mutations identified on a targeted NGS panel for cardiovascular diseases.38 Nevertheless, in 
patients for whom a specific disease, such as DMD, is strongly suspected, targeted sequencing 
of the candidate gene, including MLPA, may be preferred to ES. (2) Broadening analysis to a 
larger gene panel runs the risk of identifying VUS, as seen by the 2.5-fold higher yield of VUS 
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when we used expanded gene panels in our study. However, ES does allow for stepwise data 
analysis to minimize the number of additional VUS. The accuracy of variant interpretation can 
be improved by access to larger libraries of comprehensive sequencing data in well-phenotyped 
CM patients and well-documented controls, and with the availability of affected family members 
for segregation analyses. (3) A longer turnaround time. During our study, turnaround time was 
cut from > 26 weeks to 6 weeks, with the potential for even shorter times. (4) ES-based analysis 
is more expensive than targeted NGS. However, continuous technological innovations have 
already reduced its cost, and this trend will continue. (5) ES cannot be used to detect mutations 
in noncoding regions or in mitochondrial DNA (mtDNA), and, at the moment, our ES pipeline is 
not able to detect CNVs. However, several algorithms have been developed using a read-depth 
approach to identify CNVs in ES data39, which could increase our yield further.
WGS has several advantages over ES, including the possibility of detecting mtDNA sequence 
variants and CNVs and the elimination of time-consuming capturing steps, which is important 
for critically ill patients for whom a rapid diagnosis may influence treatment options.25 WGS may 
therefore be preferred over combined ES/CNV analysis in the future. However, given the extra 
cost of WGS, ES followed by virtual targeted stepwise analyses is currently still our preferred 
approach in a clinical diagnostic setting.
Future work and perspectives
We are now analysing the full exomes for our cohort in a research setting, using a gene-
prioritization method based on gene coexpression networks. We are also exploring the possibility 
of parallel ES and RNA sequencing to help pinpoint candidate genes and mutations. Careful 
family and cascade screening will offer more insight into the putative pathogenesis of VUS, 
while data sharing, mining and curation, in vitro and in vivo functional analyses, RNA-sequencing 
studies, and metabolomics are essential to gaining more insight into the pathogenicity of novel 
variants in genes implicated in paediatric DCM.
Conclusion
We have demonstrated that combining CNV analysis with trio-based ES yields a fast diagnosis in 
more than 50% of paediatric DCM probands, including those with possible myocarditis. To reach 
the highest increase in yield and reduce the chance of detecting noncontributory VUS or IFs, we 
propose a standardized, stepwise analysis of: (i) well-known CM genes, (ii) CNVs, (iii) all genes 
assigned to HPO cardiomyopathy, and (iv) if appropriate, genes assigned to other HPO terms in 
paediatric DCM cases. Stepwise filtering for variants in a virtual and flexible gene panel based 
on HPO terms is an effective diagnostic strategy for paediatric DCM. We report on a relatively 
small patient cohort, owing to the rarity of this disorder. However, the relevance of our approach 
should be explored in other and/or larger patient cohorts to confirm the superiority of CNV-
analysis and ES combined with targeted data analysis over other molecular and bioinformatic 
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diagnostic approaches. This also applies to the proposed strategy for adult DCM/CM patients, in 
whom an AD mode of inheritance is more prevalent than in children and in whom the phenotype 
has become clearer regarding noncardiac symptoms. The need for rapid diagnosis is generally 
less urgent in adults than in children. DCM in children may demand a different genetic approach 
from that used for adults.
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Supplementary Materials and methods
CNV-Analysis and homozygosity mapping (SNP array)
Genome-wide genotyping, using HumanCytoSNP-850K SNP array was performed, according 
to the manufacturer’s protocols (Illumina, San Diego, CA, USA). Raw data were normalized 
and converted into genotypes using GenomeStudio data analysis software and NEXUS 
(BioDiscovery Inc., El Segundo, CA, USA). CNVs were predefined as the loss of regions of DNA 
>150 kb or of at least 1 exon of a gene associated with disease in OMIM (http://ncbi.nlm.nih.gov/
omim), or the gain of regions of DNA >200 kb in size. CNVs were classified as VUS if no OMIM 
genes were located in the CNV, the deletion/duplication had not been related to a phenotype or 
reported in the literature, or the CNV did not explain the phenotype or had been described at 
least five times in a healthy control population (http://dgv.tcag.ca/dgv/app/home). Genotype files 
were uploaded into the web-based tool HomozygosityMapper in order to detect homozygous 
stretches (>10 Mb) (UCSC Genome Browser 2009 (GRCh37/hg19, http://genome.ucsc.edu/).
Exome sequencing and data analysis
Exome sequencing was performed in DNA of patients, including deceased ones, and of their 
parents. Genomic DNA was sheared by sonication (Covaris, Woburn, MA, USA). The exome was 
captured with the Agilent Sureselect XT Human All Exon V5 or V6 kit (Agilent, Santa Clara, CA, 
USA). Exome libraries were sequenced on an Illumina HiSeq2500 or a NextSeq500 instrument 
(Illumina, San Diego, CA, USA) with 2x 100 bp and 2x 150 bp paired-end reads, respectively, at 
an average coverage of 100x and with >90% of the exome covered >20x. The mean coverage 
for the coding regions of 60 well-known cardiomyopathy genes, as embedded in our targeted 
NGS panel, was 96% >20x. 
The exome sequencing data was analysed by converting the Bcl files from the sequencer to 
human readable format with the BclToFastQ tool (Illumina, San Diego, CA, USA), producing 
FastQ format. The resulting reads (in FastQ) were aligned to the human reference genome 
GRCh37/hg19 with the Burrows-Wheeler Aligner version 0.7.5a.1 Sambamba was used 
for processing the aligned reads and duplicate removal2 and then Genome Analysis Tool Kit 
(GATK) was applied for variant calling using standard settings.3,4 
WGS was done on two flow cells on a HiSeq2500HT instrument (Illumina) set to rapid-run 
modus, using 2x 100 bp paired-end sequencing (patient F26P1), or on a NextSeq500 machine 
(Illumina) on one high-output flow cell using 2x 150 bp paired-end sequencing (patient F6P1) .
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For data interpretation full data files were uploaded to Cartagenia NGS bench version 4.1 
or 4.3 (Cartagenia, Leuven, Belgium) and filtered by using an automated filter tree. We then 
generated a virtual gene panel of monogenic diseases based on the HPO term ‘cardiomyopathy’ 
(HP:0001638; http://www.human-phenotype-ontology.org/) and additional HPO terms, 
when appropriate. We supplemented the gene panel with genes absent from the HPO term 
cardiomyopathy, but associated with cardiomyopathy according to recent scientific reports.5 
At the time the data were analysed, our virtual panel consisted of at least 310 genes, when 
using only the term HP:0001638 cardiomyopathy (Supplemental Table 4). The respective 
gene panels were used for further bioinformatic filtering of the data. Variants were filtered 
on quality (read depth ≥20) and location (presence in or near (+/- 5 bp of intronic sequence) 
an exon or untranslated region). Moreover, we excluded variants with a minor allele frequency 
(MAF) of >0.5% for heterozygous variants in an autosomal dominant inheritance model and 
with a MAF>2% for homozygous or compound heterozygous variants using an autosomal 
recessive inheritance model in public databases (Genome of the Netherlands6, Exome 
Aggregation Consortium7, 1000Genomes8), as well as in our in-house database. For patients 
with consanguineous parents, homozygous stretches of >1 Mb were analysed without using 
HPO terms for filtering.
Variants were classified based on international guidelines9 using in silico prediction programs 
(Alamut, Interactive Biosoftware, Rouen, France), frequency data from the above databases, 
and information available from the literature and disease- or locus-specific databases. Likely 
pathogenic variants (class 4) affect protein function with a likelihood of 95-99% and class 
5 mutations are clearly pathogenic with sufficient genetic and/or functional evidence10 
(Supplemental Table  6). All apparently de novo variants were confirmed by conventional 
Sanger sequencing. Data analysis and interpretation for patients who underwent WGS was 
also performed as above.
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Supplementary Data 1: Evidence supporting the MYL2 variant of unknown significance 
being re-interpreted as a likely pathogenic (LP) variant
The MYL2 (NM_000432.3) c.263A>C, p.(Glu88Ala) variant was identified in two patients. Family 
studies revealed that this variant was inherited from the affected father in one family (Family 10, 
Supplemental Figure 1A). In the other family this variant was identified in the mother, who 
showed a dilated left ventricle (LV) with posterolateral hypokinesia at age 42, and in the maternal 
grandfather who was reported to have a left bundle branch block (LBBB) and a dilated LV with 
poor contractility (Family 14, Supplemental Figure 1B). In our laboratory, the same variant 
was detected in another family (A) with adult-onset DCM and non-compaction cardiomyopathy 
(NCCM) (data not shown). Haplotype analysis was performed in DNA of 3 probands and 4 
affected relatives using 14 microsatellite markers around MYL2. A shared haplotype of at least 
four markers was found covering at least a 3,932,987 bp region surrounding MYL2, suggesting 
a founder mutation. The haplotype shared between the three families is indicated in dark red. 
Index patient F10 and family A share a larger haplotype indicated in light red. Indicated in light 
yellow are the markers linked to the variant only shared by the affected family members of family 
F14 and indicated in light green are the markers linked to the variant only shared by the members 
of family A. Marker lengths (indicated as number of dinucleotide repeats) on the shared alleles 
are indicated in bold, except for those that deviate from the shared length. This difference is 
most likely the result of slippage events during replication of the respective dinucleotide repeats, 
resulting in either the insertion or deletion of one such dinucleotide. Together, our data provide 
sufficient evidence to reclassify this VUS as likely pathogenic.
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Shared haplotype surrounding the MYL2 c.263A>C mutation in patients from three different families.
NC_000012.12 release 108   Grandfather Mother Index (child) Index (child) Index Mother Uncle
CRCh38.p7   F14 F14 F14 F10 A A A
106669637 D12S1342 268 270 268 276 268 272 270 278 270 278 270 268 270 268
108310245 D12S1605 194 198 194 202 194 200 198 200 198 198 198 198 198 198
108628292 D12S84 211 205 211 215 211 213 199 213 217 203 217 203 217 203
108881391 D12S105 141 139 141 139 141 143 141 147 141 139 141 147 141 149
109386924 D12S1583 233 243 233 231 233 237 221 221 221 221 221 221 221 221
109629981 D12S1339 267 263 267 263 267 271 267 259 269 267 269 265 269 265
110121159 L1 197 203 197 205 197 193 197 197 197 197 197 203 197 203
110910819 MYL2                            
111887695 D12S1344 233 233 233 225 233 233 233 235 233 233 233 235 233 235
112856604 D12S1616 212 214 212 216 212 210 212 212 214 216 212 216 212 216
113562968 L2 182 184 182 188 182 182 186 190 190 184 188 184 188 194
114003087 L3 339 339 339 341 339 351 339 339 353 339 353 351 351 339
114690119 D12S354 189 187 189 197 189 185 189 191 195 195 195 189 195 189
115173660 D12S369 219 199 219 215 219 215 213 213 213 215 213 215 213 217
115635127 D12S1665 223 223 223 223 223 223 223 223 221 223 221 221 221 225
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◀ Supplemental Figure 1. Pedigrees of two families with the MYL2 c.263A>C, p.(Glu88Ala) variant. 
(A) F10P1. 3-methylcrotonyl-CoA-carboxylase deficiency (3-MCCD) was confirmed by enzyme analysis, 
however no likely pathogenic or pathogenic variant in MCCC1 or MCCC2 was identified (by WES and 
Sanger sequencing). This family was first reported by Visser et al.11 (B) F14P1. 
+=MYL2 variant present. 3-MCCD=3-methylcrotonyl-CoA-carboxylase deficiency,  AV=atrioventricular, 
DCM=dilated cardiomyopathy, LBBB=left bundle branch block, LV=left ventricle, mo=months, y=year. 
Supplementary Data 2: Examples illustrating the advantages of whole exome sequencing
The numbers correspond to the numbers in the main text (section headed ‘Pros and cons of our 
ES-based approach’). 
(3) In patient F6P1 we identified an additional likely pathogenic variant in TBX20. This variant 
was described by Kirk et al. in a three-generation family with three affected individuals with 
septal defects, although their cardiac valves and left ventricular (LV) function were normal.12 
However, as other TBX20 variants have been implicated in DCM, we cannot rule out that this 
variant contributes to our patient’s severe cardiac phenotype. 
(4) In patient F25P1 we identified two compound heterozygous truncating mutations in 
CEP135 as the result of analysing microcephaly related genes (HP:000252) in addition to 
cardiomyopathy-associated genes. This gene was recently associated with primary microcephaly, 
but cardiomyopathy was not reported.13,14 In 1991, Winship et al.15 reported a family with 
autosomal recessive inherited microcephaly-cardiomyopathy, an entity which was later 
confirmed by Kennedy et al.16 Interestingly, the disease course resembled that of our patient 
and bilateral fifth finger clinodactyly was observed in their patients as well as in our patient. This 
example underscores the value of adding extra HPO terms in the analysis of syndromic cases, as 
variants in genes not yet associated to the cardiomyopathy would have been missed if we had 
used solely HP:0001638 (cardiomyopathy). Moreover, this case illustrates the importance of 
a thorough physical examination by a clinical geneticist and other clinical specialists to identify 
extracardiac features that may guide optimal data analysis. 
(6) Patient F6P1, aged 3 months, presented with heart failure, which was initially misdiagnosed 
as an upper respiratory tract infection. During the clinical course, she developed an enlarged 
liver and urine analysis was compatible with GM1 gangliosidosis. More extensive analysis of 
310 cardiomyopathy-associated genes confirmed this diagnosis.
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Supplemental Table 1. Characteristics of 16 patients from 13 families excluded from ES/CNV 
analysis.
ID Cardiac phenotype Age of onset Family history Extracardiac features Genetic diagnosis SNP array




regions > 10 Mb
F33P1# DCM with restrictive 
component and LVH
5 months negative Hypotonia
Generalized myopathy
MYL2 (NM_000432.3) 403-1G>C, 
homozygous
normal










Kearns Sayre-syndrome, mtDNA del 6 Kb in 
40% of muscle cells
NP
F36P1# DCM 6 months Paternal grandfather DCM




MYL2 (NM_000432.3) 403-1G>C, 
homozygous
normal
F36P2# DCM with restrictive 
component and IVS and RV 
hypertrophy
4 months Paternal grandfather DCM




MYL2 (NM_000432.3) 403-1G>C, 
homozygous
NP




MYL2 (NM_000432.3) 403-1G>C, 
homozygous
normal
F38P1 DCM 13 yr Brother DMD Myopathy DMD (NM_004006) del exons 51-53, mat NP
F38P2 DCM 16 yr Brother DMD Myopathy, muscle biopsy: 
dystrophinopathy
DMD (NM_004006) del exons 51-53 NP






TAZ (NM_181311) c.523del, 
p.(leu175Serfs*13)
NP




DMD (NM_004006): del promotor, exon 1 NP
F40P2 DCM 14 yr Brother DMD M. quadriceps hypertrophy
Progressive myopathy
DMD (NM_004006): del promotor, exon 1 NP
F41P1 DCM 16 yr Maternal grandfather muscle disease not 
otherwise specified
Fatigue DMD (NM_004006): dup exons 35-40
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Supplemental Table 1. Characteristics of 16 patients from 13 families excluded from ES/CNV 
analysis.
ID Cardiac phenotype Age of onset Family history Extracardiac features Genetic diagnosis SNP array




regions > 10 Mb
F33P1# DCM with restrictive 
component and LVH
5 months negative Hypotonia
Generalized myopathy
MYL2 (NM_000432.3) 403-1G>C, 
homozygous
normal










Kearns Sayre-syndrome, mtDNA del 6 Kb in 
40% of muscle cells
NP
F36P1# DCM 6 months Paternal grandfather DCM




MYL2 (NM_000432.3) 403-1G>C, 
homozygous
normal
F36P2# DCM with restrictive 
component and IVS and RV 
hypertrophy
4 months Paternal grandfather DCM




MYL2 (NM_000432.3) 403-1G>C, 
homozygous
NP




MYL2 (NM_000432.3) 403-1G>C, 
homozygous
normal
F38P1 DCM 13 yr Brother DMD Myopathy DMD (NM_004006) del exons 51-53, mat NP
F38P2 DCM 16 yr Brother DMD Myopathy, muscle biopsy: 
dystrophinopathy
DMD (NM_004006) del exons 51-53 NP






TAZ (NM_181311) c.523del, 
p.(leu175Serfs*13)
NP




DMD (NM_004006): del promotor, exon 1 NP
F40P2 DCM 14 yr Brother DMD M. quadriceps hypertrophy
Progressive myopathy
DMD (NM_004006): del promotor, exon 1 NP
F41P1 DCM 16 yr Maternal grandfather muscle disease not 
otherwise specified




ID Cardiac phenotype Age of onset Family history Extracardiac features Genetic diagnosis SNP array





DMD (NM_004006) c.9204_9207del, 
p.Asn3068Lysfs*20
NP







MYL2 (NM_000432.3) 403-1G>C, 
homozygous
normal
F44P1 DCM 10 yr Mother and brother MELAS syndrome Mental retardation
Mild mixed hearing loss
MELAS syndrome: m.3243A>G (A:37.2% / 
G: 62.8%)
NP
#patients previously reported by Weterman et al.17
*patient previously reported by Almomani et al.18
AV=atrioventricular, DCM=dilated cardiomyopathy, DMD=Duchenne muscular dystrophy, 
IVS=interventricular septum, LVNC=left ventricular noncompaction, NP=not performed, LVH=left 
ventricular hypertrophy, MELAS=mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke, 
mtDNA=mitochondrial DNA, RV= right ventricle, SCD=sudden cardiac death, uk=unknown, yr=years.
Supplemental Table 2. Clinical characteristics of patients included for ES/CNV analysis. 
The patient ID is given in bold when a genetic diagnosis could be made. 






















no no uk 15 yr 12 uk no 46 Father DCM + 
myopathy
Brother DCM 
with features of 
LVNC
yes, father DCM, 
brother DCM with 
features of LVNC
- 7 yr




no no uk 14 yr 27 43 
(last 
visit)
no uk Father DCM + 
myopathy
Sister DCM with 
features of LVNC
yes, father DCM, 
sister DCM with 
features of LVNC
- 5 yr




coughing 1 w neg. 10 yr 7 uk mild LV 
conduction 
defect
199 neg. Not advised LVAD, HtX 1 yr:9 
months
F3P1 DCM no no IgG EBV pos. 
in blood
antenatal 26 37 no 404 Maternal 
grandmother 
DCM 32 yr
yes, normal - 10 yr




yes, mother DCM - 10 yr




ID Cardiac phenotype Age of onset Family history Extracardiac features Genetic diagnosis SNP array





DMD (NM_004006) c.9204_9207del, 
p.Asn3068Lysfs*20
NP







MYL2 (NM_000432.3) 403-1G>C, 
homozygous
normal
F44P1 DCM 10 yr Mother and brother MELAS syndrome Mental retardation
Mild mixed hearing loss
MELAS syndrome: m.3243A>G (A:37.2% / 
G: 62.8%)
NP
#patients previously reported by Weterman et al.17
*patient previously reported by Almomani et al.18
AV=atrioventricular, DCM=dilated cardiomyopathy, DMD=Duchenne muscular dystrophy, 
IVS=interventricular septum, LVNC=left ventricular noncompaction, NP=not performed, LVH=left 
ventricular hypertrophy, MELAS=mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke, 
mtDNA=mitochondrial DNA, RV= right ventricle, SCD=sudden cardiac death, uk=unknown, yr=years.
Supplemental Table 2. Clinical characteristics of patients included for ES/CNV analysis. 
The patient ID is given in bold when a genetic diagnosis could be made. 






















no no uk 15 yr 12 uk no 46 Father DCM + 
myopathy
Brother DCM 
with features of 
LVNC
yes, father DCM, 
brother DCM with 
features of LVNC
- 7 yr




no no uk 14 yr 27 43 
(last 
visit)
no uk Father DCM + 
myopathy
Sister DCM with 
features of LVNC
yes, father DCM, 
sister DCM with 
features of LVNC
- 5 yr




coughing 1 w neg. 10 yr 7 uk mild LV 
conduction 
defect
199 neg. Not advised LVAD, HtX 1 yr:9 
months
F3P1 DCM no no IgG EBV pos. 
in blood
antenatal 26 37 no 404 Maternal 
grandmother 
DCM 32 yr
yes, normal - 10 yr


























F3P3 DCM NP uk NP neonatal 
(dayr 8)
<10 uk no NP DCM 3rd degree 
family member
yes, normal partly 
recovered
23 yr











long QTc, nsVT 
46-
259

















neg. yes, normal, father 
not alive
died 1 yr:3 
months
F6P1 DCM high reflexes,
high muscular 








3 mo uk 10-15 no 47-
134
consanguinity not advised died 9 days
F7P1 DCM myopathy abdominal 
pain, 
pneumonia
uk 7 yr uk uk no 60 consanguinity yes, normal, father 
not alive 
died 10 yr:7 
months
F8P1 DCM with LV 
hypertrophy
hypotonia no neg. antenatal uk uk no uk neg. not advised died 6 weeks
F9P1 DCM hypertension no neg. neonatal 
(dayr 5)
20 uk no 106-
666
neg. uk recovered 11 days
F10P1# DCM 3-MCCD uk uk 4 mo 8 uk no 19-
32
Father DCM 





yes, father DCM died 9 yr:8 
months











neg. 17 yr uk uk VT 20-
342
SPCm SCD
PPCm SCD 67 yr
yes, normal died 22 days






















F3P3 DCM NP uk NP neonatal 
(dayr 8)
<10 uk no NP DCM 3rd degree 
family member
yes, normal partly 
recovered
23 yr











long QTc, nsVT 
46-
259

















neg. yes, normal, father 
not alive
died 1 yr:3 
months
F6P1 DCM high reflexes,
high muscular 








3 mo uk 10-15 no 47-
134
consanguinity not advised died 9 days
F7P1 DCM myopathy abdominal 
pain, 
pneumonia
uk 7 yr uk uk no 60 consanguinity yes, normal, father 
not alive 
died 10 yr:7 
months
F8P1 DCM with LV 
hypertrophy
hypotonia no neg. antenatal uk uk no uk neg. not advised died 6 weeks
F9P1 DCM hypertension no neg. neonatal 
(dayr 5)
20 uk no 106-
666
neg. uk recovered 11 days
F10P1# DCM 3-MCCD uk uk 4 mo 8 uk no 19-
32
Father DCM 





yes, father DCM died 9 yr:8 
months











neg. 17 yr uk uk VT 20-
342
SPCm SCD
PPCm SCD 67 yr































uk ICD, LVAD, 
HtX
15 yr
F13P1 DCM with restrictive 
component
Diagnosis recently 
revised as pericarditis 
constrictiva






type 1 en 2 
pos. in blood
14 yr 24 44 SVTs 38-
94






neg. 3 mo 17 uk atrial flutter 77 PMCm heart 
failure
yes, mother mildly 








F15P1 DCM no abdominal 








PPCp SCD 75 yr
PMCp ischemic 
CMP, SVTs, ICD
yes, father WPW ECMO, 
LVAD, HtX
7 yr




















epilepsy no uk 10 yr uk uk uk uk Mother LVH 
(hypertension)
Father AF
yes, normal died -
F18P1 DCM no no neg. 4 yr 20 uk no 22-
52
consanguinity
SCD 14 yr, 3rd 
degree family 
member
SCD 22 yr, 3rd 
degree family 
member
HCM 4th degree 
family member
yes, normal partly 
recovered
21 yr































uk ICD, LVAD, 
HtX
15 yr
F13P1 DCM with restrictive 
component
Diagnosis recently 
revised as pericarditis 
constrictiva






type 1 en 2 
pos. in blood
14 yr 24 44 SVTs 38-
94






neg. 3 mo 17 uk atrial flutter 77 PMCm heart 
failure
yes, mother mildly 








F15P1 DCM no abdominal 








PPCp SCD 75 yr
PMCp ischemic 
CMP, SVTs, ICD
yes, father WPW ECMO, 
LVAD, HtX
7 yr




















epilepsy no uk 10 yr uk uk uk uk Mother LVH 
(hypertension)
Father AF
yes, normal died -
F18P1 DCM no no neg. 4 yr 20 uk no 22-
52
consanguinity
SCD 14 yr, 3rd 
degree family 
member
SCD 22 yr, 3rd 
degree family 
member
HCM 4th degree 
family member
































3rd degree family 
member











PPCp SCD 49 yr
SCD 49 yr 3rd 
degree family 
member
PM 3rd degree 
family member











yes, normal - >22 yr
F22P1 DCM
HLHS












3rd degree family 
member 
CoA
uk died 11 months




no CMV pos. 
in urine and 
naso-pharynx









SGA, failure to 
thrive,
hypotonia,















15 yr 22 uk no 31-
49
SCD 50-60 yrs: 5 
3rd degree family 
members
uk - 1 yr






























3rd degree family 
member











PPCp SCD 49 yr
SCD 49 yr 3rd 
degree family 
member
PM 3rd degree 
family member











yes, normal - >22 yr
F22P1 DCM
HLHS












3rd degree family 
member 
CoA
uk died 11 months




no CMV pos. 
in urine and 
naso-pharynx









SGA, failure to 
thrive,
hypotonia,















15 yr 22 uk no 31-
49
SCD 50-60 yrs: 5 
3rd degree family 
members









































4 mo 13 28 no 347-
782
neg. uk partly 
recovered
5 yr
F26P1 DCM no no Rhinovirus 
pos. in naso-
pharynx
4 mo 14 30 no 47-
84






neg. 10 yr 13 22 no 28-
149
neg. uk - 3 yr





















shaped helices and 
triangular conchae




SCD 52 yr 3rd 
degree family 
member






not advised external PM, 
died
1 week









































4 mo 13 28 no 347-
782
neg. uk partly 
recovered
5 yr
F26P1 DCM no no Rhinovirus 
pos. in naso-
pharynx
4 mo 14 30 no 47-
84






neg. 10 yr 13 22 no 28-
149
neg. uk - 3 yr





















shaped helices and 
triangular conchae




SCD 52 yr 3rd 
degree family 
member











































SCD 58 PPCp yes, father DCM 57, 
brother DCM 22
ICD 20 yr








16 yr 8 uk nsVT uk neg. not advised LVAD 1 month
* = this patient carried compound heterozygous mutations in G6PT (c.1184G>T and c.1212T>C).
# = this family was previously published by Visser et al.11
3-MCCD=3-Methylcrotonyl-CoA-carboxylase deficiency, ACC=agenesis of the corpus callosum, 
AF=atrial fibrillation, CK=creatine kinase, CLP=cleft lip/palate, CMV=cytomegalovirus, CoA=coarctatio 
aortae, CVA=cerebrovascular accident, d=days, DCM=dilated cardiomyopathy, EBV=Epstein-Barr 
virus, ECG=electrocardiogram, ECMO=extracorporeal membrane oxygenation, EP=electrophysiology, 
GSD=glycogen storage disorder, HCM=hypertrophic cardiomyopathy, HLHS=hypoplastic left heart 
syndrome, HSV=Herpes simplex virus, HtX=heart transplantation, IBD=inflammatory bowel disease, 
ICD=implantable cardioverter defibrillator, ID=intellectual disability, 
IUGR=intra-uterine growth retardation, IV=interventricular, LVAD=left ventricular assistance device, 
LVEF=left ventricular ejection fraction, LVH=left ventricular hypertrophy, LVNC=left ventricular 
noncompation, mo=months, MV=mitral valve, MVP=mitral valve prolapse, neg.=negative, nsVT=non-
sustained ventricular tachycardia, PDA=patent ductus arteriosus, PM=pacemaker, pos.=positive, 
PVC=premature ventricular complex, RBBB=right bundle branch block, RSV=respiratory syncytial virus, 
RVH=right ventricular hypertrophy, SCD=sudden cardiac death, SF=shortening fraction, SGA=small for 
gestational age, SIDS=sudden infant death syndrome, SVT=supraventricular tachycardia, uk=unknown, 
URTI=upper respiratory tract infection, VSD=ventricular septal defect, VT=ventricular tachycardia, 
w=weeks, WPW=Wolff-Parkinson-White syndrome, yr=years.



































SCD 58 PPCp yes, father DCM 57, 
brother DCM 22
ICD 20 yr








16 yr 8 uk nsVT uk neg. not advised LVAD 1 month
* = this patient carried compound heterozygous mutations in G6PT (c.1184G>T and c.1212T>C).
# = this family was previously published by Visser et al.11
3-MCCD=3-Methylcrotonyl-CoA-carboxylase deficiency, ACC=agenesis of the corpus callosum, 
AF=atrial fibrillation, CK=creatine kinase, CLP=cleft lip/palate, CMV=cytomegalovirus, CoA=coarctatio 
aortae, CVA=cerebrovascular accident, d=days, DCM=dilated cardiomyopathy, EBV=Epstein-Barr 
virus, ECG=electrocardiogram, ECMO=extracorporeal membrane oxygenation, EP=electrophysiology, 
GSD=glycogen storage disorder, HCM=hypertrophic cardiomyopathy, HLHS=hypoplastic left heart 
syndrome, HSV=Herpes simplex virus, HtX=heart transplantation, IBD=inflammatory bowel disease, 
ICD=implantable cardioverter defibrillator, ID=intellectual disability, 
IUGR=intra-uterine growth retardation, IV=interventricular, LVAD=left ventricular assistance device, 
LVEF=left ventricular ejection fraction, LVH=left ventricular hypertrophy, LVNC=left ventricular 
noncompation, mo=months, MV=mitral valve, MVP=mitral valve prolapse, neg.=negative, nsVT=non-
sustained ventricular tachycardia, PDA=patent ductus arteriosus, PM=pacemaker, pos.=positive, 
PVC=premature ventricular complex, RBBB=right bundle branch block, RSV=respiratory syncytial virus, 
RVH=right ventricular hypertrophy, SCD=sudden cardiac death, SF=shortening fraction, SGA=small for 
gestational age, SIDS=sudden infant death syndrome, SVT=supraventricular tachycardia, uk=unknown, 
URTI=upper respiratory tract infection, VSD=ventricular septal defect, VT=ventricular tachycardia, 
w=weeks, WPW=Wolff-Parkinson-White syndrome, yr=years.
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Supplemental Table 3. Genes already tested in patients for which they had proved negative.
F1P1 MYBPC3, TNNI3, TNNT2, Notch1
F1P2 -




F4P1 Targeted NGS panel v1, KCNQ1, KCNH2, KCNE1, KCNE2, KCNJ2
F5P1 Targeted NGS panel v2
F6P1 -




F11P1 ALMS1, MLPA LMNA, targeted NGS panel v1
F12P1 SCN5A, TNNT2
F13P1 ACTC1, DES, MYH7, PLN, TNNI3, TNNT2
F14P1 FLNC, MLPA LMNA, targeted NGS panel v1
F15P1 DES, DSP, MYBPC3, MYH7, PLN, PRKAG2, TNNI3, TNNT2
F16P1 TNNT2
F16P2 LMNA (+MLPA), TAZ, TNNT2
F17P1 targeted NGS panel v1
F18P1 -
F19P1 targeted NGS panel v1
F20P1 -
F21P1 targeted NGS panel v2
F22P1 Notch1
F23P1 mtDNA
F24P1 targeted NGS panel v1











Targeted NGS panel v1: ABCC9, ACTC1, ACTN2, ANKRD1, BAG3, CALR3, CAV3, CRYAB, CSRP3, DES, DMD, 
DSC2, DSG2, DSP, DTNA, EMD, EYA4, GATAD1, GLA, JPH2, JUP, LAMA4, LAMP2, LDB3, LMNA, MYBPC3, 
MYH6, MYH7, MYL2, MYL3, MYPN, MYOZ1, MYOZ2, NEXN, PKP2, PLN, PRKAG2, PSEN1, PSEN2, RBM20, 
RYR2, SCN5A, SGCD, SOD2, TAZ, TBX2O, TCAP, TMEM43, TNNC1, TNNI3, TNNT2, TPM1, TTN, TXNRD2, 
VCL
Targeted NGS panel v2: Targeted NGS panel v1 + ANO5, + CTNNA3, + FHL1, + FKTN, + HCN4, + ILK, + 




Supplemental Table 4. The 310 genes included in our virtual panel (genes assigned to HPO term 
cardiomyopathy, supplemented with genes known to be associated with CM from literature). Genes in 
our core NGS targeted gene panel (designed for adult-onset cardiomyopathy) are shown in bold.
AARS2 BCS1L CTNNA3 FANCI GPR101 LAMA4 NDUFA1 PET100 PRPS1 SLC25A4 TTPA
ABCC6 BOLA3 D2HGDH FANCL GSN LAMP2 NDUFA11 PEX1 PSEN SLC2A10 TTR
ABCC9 BRAF DCAF8 FANCM GTPBP3 LCRB NDUFAF1 PEX10 PSEN2 SLX4 TXNRD2
ACAD8 BRCA2 DCHS1 FASTKD2 GYS1 LDB3 NDUFAF2 PEX11B PTPN11 SNAP29 UBR1
ACAD9 BRCC3 DES FBN1 H19 LIAS NDUFAF3 PEX12 RAB3GAP2 SOD2 VCL
ACADS BRIP1 DLD FBXL4 HADH LMNA NDUFAF4 PEX13 RAD51C SOS1 VPS13A
ACADVL BSCL2 DMD FHL1 HADHA MAP2K1 NDUFAF5 PEX14 RAF1 SPEG WFS1
ACTA1 C10ORF2 DMPK FHL2 HADHB MAP2K2 NDUFB3 PEX16 RBCK1 SYNE1 XK
ACTC1 CALR3 DNAJC19 FIG4 HAMP MGME1 NDUFB9 PEX19 RBM20 SYNE2 XPNPEP3
ACTN2 CASQ1 DOLK FKRP HBB MIB1 NDUFS1 PEX2 RET TACO1 YARS2
ADCY5 CAV1 DPM3 FKTN HCCS MLYCD NDUFS2 PEX26 RIT1 TAZ
AGK CAV3 DSC2 FLNA HCN4 MRPL3 NDUFS3 PEX3 RMND1 TBX20
AGL CDKN1C DSG2 FLNC HFE MRPL44 NDUFS4 PEX5 RMRP TCAP
AGPAT2 CHKB DSP FOS HFE2 MRPS22 NDUFS6 PEX6 RYR2 TERT
AHCY CHRM2 DTNA FOXD4 HGSNAT MTCP1 NDUFV1 PEX7 SCARB2 TGFB1
AIP CISD2 DYSF FOXRED1 HPS1 MTO1 NDUFV2 PGM1 SCN5A TGFB3
LG1 COA5 ELAC2 FTO HRAS MURC NEBL PHYH SCO2 TMEM126A
ALG6 COG7 EMD FXN HSD17B10 MUT NEU1 PIGT SDHA TMEM43
ALMS1 COL7A1 EPG5 GAA HSPB6 MYBPC3 NEXN PKP2 SDHAF1 TMEM70
ALPK3 COQ2 ERBB3 GATA4 IDH2 MYH6 NF1 PLEC SEPN1 TMPO
ANKRD1 COQ4 ERCC4 GATAD1 IDUA MYH7 NKX2-5 PLEKHM2 SGCA TNNC1
ANKRD11 COX10 EYA4 GBE1 ILK MYL2 NPPA PLN SGCB TNNI3
ANKS6 COX14 FAH GJA5 ISL1 MYL3 NRAS PMM2 SGCD TNNI3K
ANO5 COX20 FANCA GLA ITGB1BP2 MYLK2 NSD1 PNPLA2 SGSH TNNT2
APOPT1 COX6B1 FANCB GLB1 JPH2 MYOT NUBPL POLG SHOC2 TPI1
ARSB COX7B FANCC GMPPB JUP MYOZ1 PALB2 POMT1 SKI TPM1
ATP5E CPT1A FANCD2 GNAS KCNH2 MYOZ2 PCCA POU1F1 SLC19A2 TPM3
ATPAF2 CPT2 FANCE GNPTAB KCNQ1OT1 MYPN PCCB PPARG SLC22A5 TRNT1
BAG3 CRYAB FANCF GNS KLF1 NAGA PDGFRA PRDM16 SLC25A20 TSFM
BBS2 CSRP3 FANCG GPC3 KRAS NAGLU PDLIM3 PRKAG2 SLC25A3 TTN
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Supplemental Table 4. The 310 genes included in our virtual panel (genes assigned to HPO term 
cardiomyopathy, supplemented with genes known to be associated with CM from literature). Genes in 
our core NGS targeted gene panel (designed for adult-onset cardiomyopathy) are shown in bold.
AARS2 BCS1L CTNNA3 FANCI GPR101 LAMA4 NDUFA1 PET100 PRPS1 SLC25A4 TTPA
ABCC6 BOLA3 D2HGDH FANCL GSN LAMP2 NDUFA11 PEX1 PSEN SLC2A10 TTR
ABCC9 BRAF DCAF8 FANCM GTPBP3 LCRB NDUFAF1 PEX10 PSEN2 SLX4 TXNRD2
ACAD8 BRCA2 DCHS1 FASTKD2 GYS1 LDB3 NDUFAF2 PEX11B PTPN11 SNAP29 UBR1
ACAD9 BRCC3 DES FBN1 H19 LIAS NDUFAF3 PEX12 RAB3GAP2 SOD2 VCL
ACADS BRIP1 DLD FBXL4 HADH LMNA NDUFAF4 PEX13 RAD51C SOS1 VPS13A
ACADVL BSCL2 DMD FHL1 HADHA MAP2K1 NDUFAF5 PEX14 RAF1 SPEG WFS1
ACTA1 C10ORF2 DMPK FHL2 HADHB MAP2K2 NDUFB3 PEX16 RBCK1 SYNE1 XK
ACTC1 CALR3 DNAJC19 FIG4 HAMP MGME1 NDUFB9 PEX19 RBM20 SYNE2 XPNPEP3
ACTN2 CASQ1 DOLK FKRP HBB MIB1 NDUFS1 PEX2 RET TACO1 YARS2
ADCY5 CAV1 DPM3 FKTN HCCS MLYCD NDUFS2 PEX26 RIT1 TAZ
AGK CAV3 DSC2 FLNA HCN4 MRPL3 NDUFS3 PEX3 RMND1 TBX20
AGL CDKN1C DSG2 FLNC HFE MRPL44 NDUFS4 PEX5 RMRP TCAP
AGPAT2 CHKB DSP FOS HFE2 MRPS22 NDUFS6 PEX6 RYR2 TERT
AHCY CHRM2 DTNA FOXD4 HGSNAT MTCP1 NDUFV1 PEX7 SCARB2 TGFB1
AIP CISD2 DYSF FOXRED1 HPS1 MTO1 NDUFV2 PGM1 SCN5A TGFB3
LG1 COA5 ELAC2 FTO HRAS MURC NEBL PHYH SCO2 TMEM126A
ALG6 COG7 EMD FXN HSD17B10 MUT NEU1 PIGT SDHA TMEM43
ALMS1 COL7A1 EPG5 GAA HSPB6 MYBPC3 NEXN PKP2 SDHAF1 TMEM70
ALPK3 COQ2 ERBB3 GATA4 IDH2 MYH6 NF1 PLEC SEPN1 TMPO
ANKRD1 COQ4 ERCC4 GATAD1 IDUA MYH7 NKX2-5 PLEKHM2 SGCA TNNC1
ANKRD11 COX10 EYA4 GBE1 ILK MYL2 NPPA PLN SGCB TNNI3
ANKS6 COX14 FAH GJA5 ISL1 MYL3 NRAS PMM2 SGCD TNNI3K
ANO5 COX20 FANCA GLA ITGB1BP2 MYLK2 NSD1 PNPLA2 SGSH TNNT2
APOPT1 COX6B1 FANCB GLB1 JPH2 MYOT NUBPL POLG SHOC2 TPI1
ARSB COX7B FANCC GMPPB JUP MYOZ1 PALB2 POMT1 SKI TPM1
ATP5E CPT1A FANCD2 GNAS KCNH2 MYOZ2 PCCA POU1F1 SLC19A2 TPM3
ATPAF2 CPT2 FANCE GNPTAB KCNQ1OT1 MYPN PCCB PPARG SLC22A5 TRNT1
BAG3 CRYAB FANCF GNS KLF1 NAGA PDGFRA PRDM16 SLC25A20 TSFM
BBS2 CSRP3 FANCG GPC3 KRAS NAGLU PDLIM3 PRKAG2 SLC25A3 TTN
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Supplemental Table 6. Variant interpretation.
ID Mutation/variant Class Evidence
F1P1 MYH7 (NM_000257.2) c.3113T>C, p.(Leu1038Pro)
GYS1 (NM_002103.4) c.1204delA, p.(Arg402Glyfs*15)
P
P (AR; 1 mut)
PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype
PVS1, PM2 (absent)
F1P2 MYH7 (NM_000257.2) c.3113T>C, p.(Leu1038Pro)
RBM20 (NM_001134363.1) c.2042A>G, p.(Tyr681Cys)
P
VUS
PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype
PM2 (22/180914; 0.01%), PP3,
F2P1 TNNT2 (NM_001276347.1) c.629_631delAGA, p.(Lys210del), de novo
CSRP3 (NM_003476.4) c.85A>G, p.(Ser29Gly)




PS2, PM2 (absent), PP1_strong, PP5, multiple literature reports
PM2 (absent), PP3
PM2 (4/277062; 0.001%), PP2, PP3
F3P1 MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys)
TTN (NM_001267550.1) c.62710T>C, p.(Cys20904Arg)
P
VUS
PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype, multiple 
literature reports
PM2 (absent), PP3
F3P2 MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys)
MYH7 (NM_000257.2) c.328G>A, p.(Gly110Ser)
SYNE1 (NM_182961.3) c.18727G>A, p.(Glu6243Lys)





PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype, multiple 
literature reports 
PM2 (4/246172; 0.002%)
PM2 (10/277176; 0.004%), PP3
PM2 (1/ 178805; 0.0006%), PP3
F3P3 MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys) P PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype, multiple 
literature reports 
F4P1 SCN5A (NM_001099404.1) c.2512G>A, p.(Ala838Thr)
RAB3GAP2 (NM_012414.3) c.1613C>T, p.(Pro538Leu)
POLG (NM_002693.2) c.2542G>A, p.(Gly848Ser)
TNNC1 (NM_003280.2) c.304C>T, p.(Arg102Cys)
LDB3 (NM_007078.2) c.1051A>G, p.(Thr351Ala)
MYH6 (NM_002471.3) c.4193G>A, p.(Arg1398Gln)
ANKRD11 (NM_001256182.1) c.244C>T, p.(Arg82Trp)
DTNA (NM_001198939.1) c.153C>G, p.(His51Gln), pat










PM2 (absent), PP1, PP3, PP4
PM2 (10/246116; 0.004%), PP3
PM2 (49/277176; 0.02%), PP3, described for progressive external ophthalmoplegia, not cardiac anomalies.
PM2 (3/246248; 0.001%), PP3
PM2 (118/273888; 0.04%), population freq. is high, but multiple literature reports 
PM2 (102/277070; 0.04%), population freq. is high, but multiple literature reports, PP3
PM2 (absent), PP3
PM2 (1/ 245064; 0.0004%), PP3
PM2 (17/ 277018; 0.006%), PP3
F5P1 TTN (NM_001267550.1) c.89314G>T, p.(Glu29772*)
SGSH (NM_000199.3) c.892T>C, p.(Ser298Pro)
CPS1 (NM_001875.4) c.295C>A, p.(Pro99Thr)
WFS1 (NM_006005.3) c.605A>G, p.(Glu202Gly)
SYNE2 (NM_182914.2) c.20039G>A, p.(Arg6680Gln)
PLEKHM2 (NM_015164) c.820G>A, p.(Glu274Lys)
LP






PM2 (30/276828; 0.01%), multiple literature reports 
PM2 (13/276936; 0.005%), PP3
PM2 (1/244766; 0.0004%), PP3
PM2 (7/244792; 0.003%)
PM2 (12/192336; 0.006%), PP3
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Supplemental Table 6. Variant interpretation.
ID Mutation/variant Class Evidence
F1P1 MYH7 (NM_000257.2) c.3113T>C, p.(Leu1038Pro)
GYS1 (NM_002103.4) c.1204delA, p.(Arg402Glyfs*15)
P
P (AR; 1 mut)
PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype
PVS1, PM2 (absent)
F1P2 MYH7 (NM_000257.2) c.3113T>C, p.(Leu1038Pro)
RBM20 (NM_001134363.1) c.2042A>G, p.(Tyr681Cys)
P
VUS
PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype
PM2 (22/180914; 0.01%), PP3,
F2P1 TNNT2 (NM_001276347.1) c.629_631delAGA, p.(Lys210del), de novo
CSRP3 (NM_003476.4) c.85A>G, p.(Ser29Gly)




PS2, PM2 (absent), PP1_strong, PP5, multiple literature reports
PM2 (absent), PP3
PM2 (4/277062; 0.001%), PP2, PP3
F3P1 MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys)
TTN (NM_001267550.1) c.62710T>C, p.(Cys20904Arg)
P
VUS
PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype, multiple 
literature reports
PM2 (absent), PP3
F3P2 MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys)
MYH7 (NM_000257.2) c.328G>A, p.(Gly110Ser)
SYNE1 (NM_182961.3) c.18727G>A, p.(Glu6243Lys)





PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype, multiple 
literature reports 
PM2 (4/246172; 0.002%)
PM2 (10/277176; 0.004%), PP3
PM2 (1/ 178805; 0.0006%), PP3
F3P3 MYH7 (NM_000257.2) c.5754C>G, p.(Asn1918Lys) P PM2 (absent), PP1_strong, PP2, PP3, multiple unrelated probands with same phenotype, multiple 
literature reports 
F4P1 SCN5A (NM_001099404.1) c.2512G>A, p.(Ala838Thr)
RAB3GAP2 (NM_012414.3) c.1613C>T, p.(Pro538Leu)
POLG (NM_002693.2) c.2542G>A, p.(Gly848Ser)
TNNC1 (NM_003280.2) c.304C>T, p.(Arg102Cys)
LDB3 (NM_007078.2) c.1051A>G, p.(Thr351Ala)
MYH6 (NM_002471.3) c.4193G>A, p.(Arg1398Gln)
ANKRD11 (NM_001256182.1) c.244C>T, p.(Arg82Trp)
DTNA (NM_001198939.1) c.153C>G, p.(His51Gln), pat










PM2 (absent), PP1, PP3, PP4
PM2 (10/246116; 0.004%), PP3
PM2 (49/277176; 0.02%), PP3, described for progressive external ophthalmoplegia, not cardiac anomalies.
PM2 (3/246248; 0.001%), PP3
PM2 (118/273888; 0.04%), population freq. is high, but multiple literature reports 
PM2 (102/277070; 0.04%), population freq. is high, but multiple literature reports, PP3
PM2 (absent), PP3
PM2 (1/ 245064; 0.0004%), PP3
PM2 (17/ 277018; 0.006%), PP3
F5P1 TTN (NM_001267550.1) c.89314G>T, p.(Glu29772*)
SGSH (NM_000199.3) c.892T>C, p.(Ser298Pro)
CPS1 (NM_001875.4) c.295C>A, p.(Pro99Thr)
WFS1 (NM_006005.3) c.605A>G, p.(Glu202Gly)
SYNE2 (NM_182914.2) c.20039G>A, p.(Arg6680Gln)
PLEKHM2 (NM_015164) c.820G>A, p.(Glu274Lys)
LP






PM2 (30/276828; 0.01%), multiple literature reports 
PM2 (13/276936; 0.005%), PP3
PM2 (1/244766; 0.0004%), PP3
PM2 (7/244792; 0.003%)




ID Mutation/variant Class Evidence
F6P1 GLB1 (NM_000404.2) c.176G>A, p.(Arg59His) (homozygous)
TBX20 (NM_001077653.2) c.456C>G, p.(Ile152Met) (LP)
MYBPC3 (NM_000256.3) c.194C>T, p.(Thr65Met)
MYH6 (NM_002471.3) c.4037G>A, p.(Arg1346Gln)
RAF1 (NM_002880.3) c.29C>T, p.(Thr10Met)
LIAS (NM_006859.3) c.1114C>A, p.(Leu372Ile)
ABCB4 (NM_018849.2) c.3829G>T, p.(Val1277Phe)
SERPINA1 (NM_001127701.1) c.936A>T, p.(Leu312Phe)
SERPINA1 (NM_001127701.1) c.952A>T, p.(Thr318Ser)
FANCA (NM_001286167.1) c.871A>G, p.(Thr291Ala)
PTRF (NM_012232.5) c.7G>A, p.(Asp3Asn)
SDHAF1 (NM_001042631.2) c.334C>T, p.(Pro112Ser)














PM2 (9/246126; 0.004%), PP3, PP4, PP5, multiple literature reports 
PM2 (5/246272; 0.002%), variant previously described in literature15
PM2 (absent), PP3
PM2 (2/276434; 0.0007%), PP3
PM2 (3/246242; 0.001%), PP3
PM2 (absent)






PM2 (3/173424; 0.002%), PP3
F7P1 SPEG (NM_005876) c.9185_9187delTGG, p.Val3062del (homozygous) P PM2 (absent), PP2, PP3, PP4
F8P1 TPM1 (NM_001018004.1) c.475G>A, p.(Asp159Asn), de novo
MYPN (NM_032578.3) c.416_421delinsTGG, p.(Gln139_
Cys141delinsLeuGly)
NEBL (NM_006393.2) c.1715C>T, p.(Ser572Phe)





PS2, PM2 (absent), PP2, PP3
PM2 (absent)
PM2 (2/245406; 0.002%), PP3
PM2 (absent)
F9P1 MYH7 (NM_000257.2) c.3100-2A>C
PEX1 (NM_000466.2) c.2528G>A, p.(Gly843Asp)
FHL2 (NM_201555.1) c.487_488delGT, p.(Val163Serfs*42)
DSP (NM_004415.2) c.8300C>G, p.(Thr2767Ser)
LP
P (AR; 1 mut)
VUS
VUS
PM2 (5/277180; 0.002%), PP1, PP3 (RNA splice predictions), multiple unrelated probands with 
same phenotype
PM2 (87/277072; 0.03%), PP3, multiple literature reports
PM2 (absent)
PM2 (absent)
F10P1 MYL2 (NM_000432.3) c.263A>C, p.(Glu88Ala)
TMPO (NM_001032283.2) c.232G>C, p.(Gly78Arg)
PCCA (NM_000282.3) c.1896A>G, p.(=)
FKBP10 (NM_021939.3) c.210C>G, p.(Asn70Lys)






PM2 (absent), PP1_moderate, PP3, PP4, see also Supplemental data 1
PM2 (absent)
PM2 (111/176396; 0.07%), PP3 (RNA splice predictions)
PM2 (5/246084; 0.002%), PP3
PM2 (2/246234; 0.0008%)
F11P1 PRDM16 (NM_022114) c.1882G>A, p.(Asp628Asn) VUS PM2 (35/265194; 0.02%); PP3
F12P1 TERT (NM_198253.2) c.1323_1325delGGA, p.(Glu441del)
KCNH2 (NM_000238.3) c.3052C>G, p.(Pro1018Ala) 
VUS
VUS
PM2 (9/14600; 0.062%); PP2
PM2 (4/150574; 0.003%), PP2
F13P1 GSN (NM_000177.4) c.130dupG, p.(Val44Glyfs*68)
KRAS (NM_033360.2) c.540T>A, p.(Cys180*)





PM2 (22/ 276946); 0.008%)
PM2 (39/199818 ; 0.02%), PP3
F14P1 MYL2 (NM_000432.3) c.263A>C, p.(Glu88Ala), mat (LP) LP PM2 (absent), PP1_moderate, PP3, PP4, see also Supplemental data 1
F15P1 SYNE1 (NM_182961.3) c.25381G>A, p.(Glu8461Lys)
SYNE1 (NM_182961.3) c.26165G>A, p.(Gly8722Asp)
RYR2 (NM_001035.2) c.14757-7_14757-6delinsAT
SCN5A (NM_001099404.1) c.2924G>A, p.(Arg975Gln)






PP3, variant previously described in literature16
PM2 (absent)
PM2 (absent), multiple literature reports
PM2 (10/270136; 0.003%)
PM2 (absent)




ID Mutation/variant Class Evidence
F6P1 GLB1 (NM_000404.2) c.176G>A, p.(Arg59His) (homozygous)
TBX20 (NM_001077653.2) c.456C>G, p.(Ile152Met) (LP)
MYBPC3 (NM_000256.3) c.194C>T, p.(Thr65Met)
MYH6 (NM_002471.3) c.4037G>A, p.(Arg1346Gln)
RAF1 (NM_002880.3) c.29C>T, p.(Thr10Met)
LIAS (NM_006859.3) c.1114C>A, p.(Leu372Ile)
ABCB4 (NM_018849.2) c.3829G>T, p.(Val1277Phe)
SERPINA1 (NM_001127701.1) c.936A>T, p.(Leu312Phe)
SERPINA1 (NM_001127701.1) c.952A>T, p.(Thr318Ser)
FANCA (NM_001286167.1) c.871A>G, p.(Thr291Ala)
PTRF (NM_012232.5) c.7G>A, p.(Asp3Asn)
SDHAF1 (NM_001042631.2) c.334C>T, p.(Pro112Ser)














PM2 (9/246126; 0.004%), PP3, PP4, PP5, multiple literature reports 
PM2 (5/246272; 0.002%), variant previously described in literature15
PM2 (absent), PP3
PM2 (2/276434; 0.0007%), PP3
PM2 (3/246242; 0.001%), PP3
PM2 (absent)






PM2 (3/173424; 0.002%), PP3
F7P1 SPEG (NM_005876) c.9185_9187delTGG, p.Val3062del (homozygous) P PM2 (absent), PP2, PP3, PP4
F8P1 TPM1 (NM_001018004.1) c.475G>A, p.(Asp159Asn), de novo
MYPN (NM_032578.3) c.416_421delinsTGG, p.(Gln139_
Cys141delinsLeuGly)
NEBL (NM_006393.2) c.1715C>T, p.(Ser572Phe)





PS2, PM2 (absent), PP2, PP3
PM2 (absent)
PM2 (2/245406; 0.002%), PP3
PM2 (absent)
F9P1 MYH7 (NM_000257.2) c.3100-2A>C
PEX1 (NM_000466.2) c.2528G>A, p.(Gly843Asp)
FHL2 (NM_201555.1) c.487_488delGT, p.(Val163Serfs*42)
DSP (NM_004415.2) c.8300C>G, p.(Thr2767Ser)
LP
P (AR; 1 mut)
VUS
VUS
PM2 (5/277180; 0.002%), PP1, PP3 (RNA splice predictions), multiple unrelated probands with 
same phenotype
PM2 (87/277072; 0.03%), PP3, multiple literature reports
PM2 (absent)
PM2 (absent)
F10P1 MYL2 (NM_000432.3) c.263A>C, p.(Glu88Ala)
TMPO (NM_001032283.2) c.232G>C, p.(Gly78Arg)
PCCA (NM_000282.3) c.1896A>G, p.(=)
FKBP10 (NM_021939.3) c.210C>G, p.(Asn70Lys)






PM2 (absent), PP1_moderate, PP3, PP4, see also Supplemental data 1
PM2 (absent)
PM2 (111/176396; 0.07%), PP3 (RNA splice predictions)
PM2 (5/246084; 0.002%), PP3
PM2 (2/246234; 0.0008%)
F11P1 PRDM16 (NM_022114) c.1882G>A, p.(Asp628Asn) VUS PM2 (35/265194; 0.02%); PP3
F12P1 TERT (NM_198253.2) c.1323_1325delGGA, p.(Glu441del)
KCNH2 (NM_000238.3) c.3052C>G, p.(Pro1018Ala) 
VUS
VUS
PM2 (9/14600; 0.062%); PP2
PM2 (4/150574; 0.003%), PP2
F13P1 GSN (NM_000177.4) c.130dupG, p.(Val44Glyfs*68)
KRAS (NM_033360.2) c.540T>A, p.(Cys180*)





PM2 (22/ 276946); 0.008%)
PM2 (39/199818 ; 0.02%), PP3
F14P1 MYL2 (NM_000432.3) c.263A>C, p.(Glu88Ala), mat (LP) LP PM2 (absent), PP1_moderate, PP3, PP4, see also Supplemental data 1
F15P1 SYNE1 (NM_182961.3) c.25381G>A, p.(Glu8461Lys)
SYNE1 (NM_182961.3) c.26165G>A, p.(Gly8722Asp)
RYR2 (NM_001035.2) c.14757-7_14757-6delinsAT
SCN5A (NM_001099404.1) c.2924G>A, p.(Arg975Gln)






PP3, variant previously described in literature16
PM2 (absent)






ID Mutation/variant Class Evidence
F16P1 TNNT2 (NM_001276347.1) c.522G>C, p.(Lys174Asn)




PM2 (12/277190; 0.004%), PP3
F16P2 TNNT2 (NM_001276347.1) c.522G>C, p.(Lys174Asn)
APC (NM_000038.5) c.4625C>G, p.(Pro1542Arg)
SYNE1 (NM_182961.3) c.6589T>C, p.(Ser2197Pro)
OCA2 (NM_000275.2) c.1327G>A, p.(Val443Ile)
SLC26A4 (NM_000441.1) c.2235G>A, p.(=), de novo










PM2 (834/275824; 0.3%), multiple literature reports
PM2 (3/245930; 0.001%), PP3 (RNA splice predictions)
PM2 (1/245982; 0.0004%), PP3
F17P1 PMM2 (NM_000303.2) c.422G>A, p.(Arg141His)
DPYD (NM_000110.3) c.557A>G, p.(Tyr186Cys)
NDUFA10 (NM_004544.3) c.332A>G, p.(Asn111Ser) 
NDUFA10 (NM_004544.3) c.506T>C, p.(Phe169Ser)
SCN5A (NM_001099404.1) c.5860G>A, p.(Glu1954Lys)





PP3, PP5, multiple literature reports
PP3, PP5
PM2 (5/277246; 0.002%)
PM2 (5/277238; 0.002%), PP3
PM2 (12/274284; 0.004%)
F18P1 LDB3 (NM_001171610) c.676G>A, p.(Gly226Arg) VUS PM2 (12/261298; 0.005%), PP3
F19P1 DTNA (NM_001392.4) c.*5A>G VUS PM2 (absent)
F20P1 SDHA (NM_001294332.1) c.544G>C, p.(Glu182Gln)




PM2 (56/276682; 0.02%), PP3
F21P1 TTN (NM_001267550.1) c.98119G>C, p.(Asp32707His)
TTN (NM_001267550.1) c.11996A>G, p.(Asn3999Ser)
PLEC (NM_201380.3) c.8321C>T, p.(Ala2774Val)
PLEC (NM_201380.3) c.10964A>G, p.(His3655Arg)






PM2 (6/276158; 0.002%), PP3
PM2 (34/ 276138; 0.01%), PP3
PM2 (5/255398); 0.002%)
PM2 (8/277150; 0.003%)
PM2 (1/245554; 0.0004%), PP3
F22P1 NDUFS4 (NM_002495.2) c.278A>G, p.(Asn93Ser)




PM2 (10/ 276172; 0.004%)
F23P1 TTN (NM_001267550.1) c.35189_35191delAAG, p.(Glu11730del)




PM2 (6/276954; 0.002%), PP3
F24P1 ANKRD11 (NM_001256182.1) c.2880G>C, p.(Glu960Asp)





F25P1 CEP135 (NM_025009.4) c.874C>T, p.(Arg292*)
c.3118_3121delAACA, p.(Asn1040Glufs*9)
DMD (NM_004006.2) c.1536C>A, p.(His512Gln)
PCCA (NM_000282.3) c.1289G>A, p.(Arg430Gln)






PVS1, PM2 (10/276804; 0.004%), PP4
PVS1, PM2 (5/119936; 0.004%), PP4
PM2 (5/200311; 0.003%), PP3
PM2 (11/245084; 0.004%), PP3
PM2 (514/277186; 0.2%), PP3
F26P1 TTN (NM_001267550.1) c.13048G>A, p.(Val4350Met)





F27P1 RAB3GAP2 (NM_012414.3) c.683_684delTT, p.(Leu228Profs*16)
TTN (NM_001267550.1) c.55355C>G, p.(Ser18452Cys)
TTN (NM_001267550.1) c.43700G>C, p.(Arg14567Thr)
COL7A1 (NM_000094.3) c.6977C>A, p.(Pro2326Gln)
POLG (NM_002693.2) c.3064C>G, p.(Leu1022Val)
EPG5 (NM_020964.2) c.4169A>G, p.(Tyr1390Cys)
















ID Mutation/variant Class Evidence
F16P1 TNNT2 (NM_001276347.1) c.522G>C, p.(Lys174Asn)




PM2 (12/277190; 0.004%), PP3
F16P2 TNNT2 (NM_001276347.1) c.522G>C, p.(Lys174Asn)
APC (NM_000038.5) c.4625C>G, p.(Pro1542Arg)
SYNE1 (NM_182961.3) c.6589T>C, p.(Ser2197Pro)
OCA2 (NM_000275.2) c.1327G>A, p.(Val443Ile)
SLC26A4 (NM_000441.1) c.2235G>A, p.(=), de novo










PM2 (834/275824; 0.3%), multiple literature reports
PM2 (3/245930; 0.001%), PP3 (RNA splice predictions)
PM2 (1/245982; 0.0004%), PP3
F17P1 PMM2 (NM_000303.2) c.422G>A, p.(Arg141His)
DPYD (NM_000110.3) c.557A>G, p.(Tyr186Cys)
NDUFA10 (NM_004544.3) c.332A>G, p.(Asn111Ser) 
NDUFA10 (NM_004544.3) c.506T>C, p.(Phe169Ser)
SCN5A (NM_001099404.1) c.5860G>A, p.(Glu1954Lys)





PP3, PP5, multiple literature reports
PP3, PP5
PM2 (5/277246; 0.002%)
PM2 (5/277238; 0.002%), PP3
PM2 (12/274284; 0.004%)
F18P1 LDB3 (NM_001171610) c.676G>A, p.(Gly226Arg) VUS PM2 (12/261298; 0.005%), PP3
F19P1 DTNA (NM_001392.4) c.*5A>G VUS PM2 (absent)
F20P1 SDHA (NM_001294332.1) c.544G>C, p.(Glu182Gln)




PM2 (56/276682; 0.02%), PP3
F21P1 TTN (NM_001267550.1) c.98119G>C, p.(Asp32707His)
TTN (NM_001267550.1) c.11996A>G, p.(Asn3999Ser)
PLEC (NM_201380.3) c.8321C>T, p.(Ala2774Val)
PLEC (NM_201380.3) c.10964A>G, p.(His3655Arg)






PM2 (6/276158; 0.002%), PP3
PM2 (34/ 276138; 0.01%), PP3
PM2 (5/255398); 0.002%)
PM2 (8/277150; 0.003%)
PM2 (1/245554; 0.0004%), PP3
F22P1 NDUFS4 (NM_002495.2) c.278A>G, p.(Asn93Ser)




PM2 (10/ 276172; 0.004%)
F23P1 TTN (NM_001267550.1) c.35189_35191delAAG, p.(Glu11730del)




PM2 (6/276954; 0.002%), PP3
F24P1 ANKRD11 (NM_001256182.1) c.2880G>C, p.(Glu960Asp)





F25P1 CEP135 (NM_025009.4) c.874C>T, p.(Arg292*)
c.3118_3121delAACA, p.(Asn1040Glufs*9)
DMD (NM_004006.2) c.1536C>A, p.(His512Gln)
PCCA (NM_000282.3) c.1289G>A, p.(Arg430Gln)






PVS1, PM2 (10/276804; 0.004%), PP4
PVS1, PM2 (5/119936; 0.004%), PP4
PM2 (5/200311; 0.003%), PP3
PM2 (11/245084; 0.004%), PP3
PM2 (514/277186; 0.2%), PP3
F26P1 TTN (NM_001267550.1) c.13048G>A, p.(Val4350Met)





F27P1 RAB3GAP2 (NM_012414.3) c.683_684delTT, p.(Leu228Profs*16)
TTN (NM_001267550.1) c.55355C>G, p.(Ser18452Cys)
TTN (NM_001267550.1) c.43700G>C, p.(Arg14567Thr)
COL7A1 (NM_000094.3) c.6977C>A, p.(Pro2326Gln)
POLG (NM_002693.2) c.3064C>G, p.(Leu1022Val)
EPG5 (NM_020964.2) c.4169A>G, p.(Tyr1390Cys)















ID Mutation/variant Class Evidence
F28P1 RBM20 (NM_001134363.2) c.2042A>G, p.(Tyr681Cys), pat VUS PM2 (22/180914; 0.01%), PP3
F29P1 FLNC (NM_001458) c.1673G>A, p.(Arg558His)
SPEG (NM_005876.4) c.4822G>A, p.(Gly1608Ser) (AR)




PM2 (11/277132 ; 0.004%), PP3
PM2 (absent), PP3
PM2 (absent), PP3
F30P1 MYH7 (NM_000257.2) c.1633G>A, p.(Asp545Asn) and c.2863G>A, 
p.(Asp955Asn) in cis
P PM2 (absent), PP1_strong, PP2, PP3, multiple literature reports, multiple unrelated probands with 
same phenotype
F31P1 Negative
Supplemental Table 6. Variant interpretation.
Variants were classified based on the recommendations of Richard et al.9 The following criteria 
were applied: 
PVS1, null variant (nonsense, frameshift, canonical ± 1 or 2 splice sites, initiation codon, single 
or multi-exon deletion) in a gene where loss of function (LoF) is a known mechanism of disease; 
PS2, de novo (both maternity and paternity confirmed) in a patient with the disease and no family 
history; 
PM2, absent from controls (or extremely rare, note the difference between AD or AR 
inheritance), and indicated between brackets are allele count/allele number and allele frequency 
for gnomAD ALL. 
PP1, cosegregation with disease in multiple affected family members in a gene definitively known 
to cause the disease. Note: this may be used as stronger evidence with increasing segregation 
data. When appropriate, indicated as PP1_moderate or PP1_strong; 
PP2, missense variant (or in frame indel) in a gene that has a low rate of benign missense variation 
and in which missense variants are a common mechanism of disease; 
PP3, multiple lines of computational evidence support a deleterious effect on the gene or the 
gene product (conservation, evolutionary, splicing, impact); 
PP4, patient’s phenotype or family history is highly specific for a disease with a single genetic 
aetiology; 




ID Mutation/variant Class Evidence
F28P1 RBM20 (NM_001134363.2) c.2042A>G, p.(Tyr681Cys), pat VUS PM2 (22/180914; 0.01%), PP3
F29P1 FLNC (NM_001458) c.1673G>A, p.(Arg558His)
SPEG (NM_005876.4) c.4822G>A, p.(Gly1608Ser) (AR)




PM2 (11/277132 ; 0.004%), PP3
PM2 (absent), PP3
PM2 (absent), PP3
F30P1 MYH7 (NM_000257.2) c.1633G>A, p.(Asp545Asn) and c.2863G>A, 
p.(Asp955Asn) in cis
P PM2 (absent), PP1_strong, PP2, PP3, multiple literature reports, multiple unrelated probands with 
same phenotype
F31P1 Negative
PP5, reputable source has recently reported variant as pathogenic, but the evidence is not 
available to the laboratory for them to perform an independent evaluation. 
In addition we have added the criteria “multiple unrelated probands with same phenotype” and 
“multiple reports in literature” or “described in literature”. Variants classified as pathogenic (P) or likely 




Supplemental Table 5 (HPO terms) is linked to the online version of the paper at 
https://www.nature.com/articles/gim20189#Sec22.
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